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1. Introduction 
The worldwide annual incidence of breast cancer exceeds one 
million cases, with statistics from the UK showing that the 
lifetime risk of a woman developing the disease is 1 in 8.1 Early 
detection of tumors is known to be crucial for improving survival 
rates.2 The estrogen receptor (ER) is overexpressed in a major 
subtype of breast cancer, referred to as "ER-positive" (ER+), and 
was the first protein to be used as a diagnostic and prognostic 
biomarker for breast cancer.3 ER+ tumors are often responsive to 
aromatase inhibitors or to selective ER modulator (SERM) 
therapies.3 However, the clinical use of SERM therapies is 
limited by drug resistance,4 and the use of immunohistochemical 
staining to detect ERs for diagnostic purposes suffers from 
standardization problems.5 Consequently, new therapeutic leads 
and diagnostic biomarkers for ER+ tumors are desirable. 
Proteomic6 and microarray7 studies have identified human 
arylamine N-acetyltransferase 1 (hNAT1) as one of the ten most 
highly overexpressed genes in ER+ tumors; furthermore, this 
overexpression inversely correlates to tumor grade.8 More 
recently hNAT1 overexpression in male breast cancers has also 
been reported.9 The corresponding enzyme hNAT1 is therefore of 
interest as a surrogate diagnostic and prognostic biomarker for 
ER+ tumors. Furthermore, studies suggest that hNAT1 could also 
be a novel therapeutic target against ER+ breast cancer.10 Key 
evidence includes: the discovery of hallmarks of oncogenic 
potential in the non-cancerous breast cell line HB4a induced to 
overexpress hNAT1;6 and the reduction in cell proliferation and 
invasiveness observed in the MDA-MB-231 breast cancer cell 
line (which expresses high levels of hNAT1) when either hNAT1 
was knocked down by shRNA or the cells were treated with 
inhibitors of hNAT1.11 
NATs are a family of xenobiotic metabolizing enzymes found 
in both eukaryotic and prokaryotic organisms, which catalyze the 
transfer of an acetyl group from acetyl coenzyme A (AcCoA) to a 
xenobiotic substrate, such as arylamines, arylhydroxylamines, 
arylhydrazines, and N-alkylarylamines.12 The human genome 
codes for two functional NAT genes: hNAT1 and hNAT2. The 
gene product hNAT2 is implicated in phase II drug metabolism 
and is abundant in liver and intestinal cells,12a whilst hNAT1 has 
a widespread tissue distribution13 and is reported to play a role in 
cofactor homeostasis;14 studies suggest eukaryotic homologues of 
hNAT1 are involved in growth and development.15 Estrogen 
levels may also have an effect on hNAT1 expression.16 
Aside from the discovery that the SERM tamoxifen 1 reduces 
hNAT1 activity in vitro,17 the first compounds identified as 
hNAT1 inhibitors were found to be non-selective for hNAT1 and 
to act via covalent modification of the catalytic Cys68 residue;18 
these include alkylating agents as well as the widely prescribed 
chemotherapeutic agent cisplatin.19 
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Figure 1: (a) Examples of hNAT1 inhibitors reported in the literature.6, 20 (b) Compound 4 is deprotonated selectively in the presence of hNAT1 with a 
distinctive concomitant color change; this process is driven by sequestration of the conjugate base of 4 by the Arg127 residue of hNAT1.21 (N.D. = not 
determined.) 
 
More recently, rhodanine 2 and naphthoquinone 3 have been 
identified as inhibitors of hNAT1 (and its murine homologue 
mNat2)22 and were found to be selective over a variety of other 
NATs including hNAT2;20 additionally both 2 and 3 inhibited 
hNAT1 activity in cell extracts from the ER+ breast cancer cell 
line ZR-75-1 (Figure 1(a)).20, 23  
The reversible, competitive naphthoquinone inhibitor 3 
proved to be of particular interest, because it was found that 3 
undergoes a distinctive color change from red to blue in the 
presence of hNAT1 and mNat2, but not any other NAT isoform 
tested.23 Subsequently spectroscopic, chemical, molecular 
modeling and biochemical studies have been carried out on a 
close analogue of 3, the dimethyl-substituted 4, which has a 
similar potency to 3 against hNAT1 and mNat2 (Figure 1(b)).21 
These studies demonstrated that this color change is driven by 
sequestration of the conjugate base of 4 (pKa ~9.2), mediated by 
Arg127 in the active site of hNAT1 or mNat2.21  
This observed color change leads to the possibility that 4 
could act as a direct in vitro probe for the presence of native 
hNAT1, without the conventional need for protein tagging or 
antibody staining.24 Potentially, any specific small molecule 
inhibitors of hNAT1 could additionally be valuable leads for a 
new drug therapy. However, for the potential of these 
naphthoquinones as probes for hNAT1 to be realized, it is 
believed that both the binding potency and molar absorption 
coefficient need to be increased. We describe here our 
preliminary structure-activity relationship and optimization 
studies. 
 
2. Results and Discussion 
2.1. Quantification of [hNAT1] in Cell Extracts from the 
Breast Cancer Cell Line ZR-75-1 
The approximate level of hNAT1 in a representative breast 
cancer cell line (ZR-75-1) was determined using immunoblotting, 
to gain an understanding of the sensitivity required in a probe for 
hNAT1 detection in cells.  
The twelve C-terminal residues of hNAT1 and mNat2 are 
identical and distinct from those of hNAT2. This has allowed 
generation of a specific antibody which recognizes both hNAT1 
and mNat213a, 15d, 25 with equal levels of sensitivity.26 
 
 
 
Figure 2: Immunohistochemical quantification of hNAT1 in ZR-75-1 
cell lysate. (a) Detection of purified recombinant mNat2, and hNAT1 in cell 
lysate by Western Blotting. Molecular weights and positions of the protein 
bands in the SeeBlue® Plus2 Pre-Stained Standard used are shown on the left. 
Lanes: 1-4 0.0125, 0.125, 0.625 and 1.25 ng/µL mNat2; 5-7: 10-, 100- and 
1000-fold diluted ZR-75-1 cell lysate of 5 x 107 cells/mL. (b) Detection of 
purified recombinant mNat2 (M) and hNAT1 in cell lysate (H) by dot 
blotting as native (N) and denatured (D) proteins. Native protein samples 
were dissolved in an equal volume of buffer (200 mM Tris.HCl (pH 8)), 
while denatured proteins were prepared in an equal volume of buffer with 
2% (w/v) SDS and heated to 95 °C for 5 min. Lanes: M1 0.031 ng/µL; 
M2 0.0078 ng/µL; H1 500-fold diluted cell lysate of 5 x 107 cells/mL; 
H2 2500-fold diluted lysate. 
 
A Western blot was performed with both pure recombinant 
mNat2 and ZR-75-1 cell extracts, and a single band at ~34 kDa 
Compound 
Enzyme 
hNAT1 mNat2 WT 
mNat2 
R127G 
mNat2 
R127L 
4 
IC50 (µM) 5.3 1.9 51.7 102.5 
λmax (nm) 585 625 498 498 
5 
IC50 (µM) 5.8 > 150 N.D. N.D. 
λmax (nm) 476 490 N.D. N.D. 
 
 
 
  1 2 3 
 
 (a) 
 (b) 
 
4 X = H  
λmax (pH 8) = 498 nm 
 
5 X = Me 
λmax (pH 8) = 496 nm 
  
(corresponding to the relevant NAT protein) was observed for all 
samples (Figure 2(a)). A comparison of lanes 3 and 6 suggested 
that there is less than 62.5 ng/µL of hNAT1 (i.e. less than 62.5 ng 
hNAT1 per 5 x 104 cells). 
Subsequently, dot-blotting studies were carried out, varying 
the concentrations of pure recombinant mNat2 and ZR-75-1 cell 
extracts, under both native and denaturing conditions 
(Figure 2(b)). Comparing lanes M2 and H2, there appeared to be 
greater than 19.5 ng of native hNAT1 per 5 x 104 cells. It can 
also be noted that the antibody had a higher affinity for native 
hNAT1 than denatured hNAT1, a result which is consistent with 
previous studies.26 
These experiments therefore showed that the concentration of 
hNAT1 in the ZR-75-1 cell extract is approximately 0.6-1.2 µM 
(20-60 ng/µL); this informed us of the level of sensitivity 
required of a colorimetric probe for detecting hNAT1 in such cell 
extracts. Bradford assays show that the total cellular protein 
concentration is 11.5 µg/µL, and hence the percentage of hNAT1 
in the ZR-75-1 cell proteome is around 0.2-0.5%. 
In separate experiments, the minimum hNAT1:inhibitor ratio 
to enable the unambiguous determination of a colorimetric shift 
of 4 spectroscopically was determined. It was predicted that 
based on the calculated Kd for 4 (4.9 µM) and a 1:1 binding 
ratio,23 an excess of the protein would be required for every 
inhibitor molecule to bind and change color. The required 
hNAT1:inhibitor ratio would also be expected to decrease with 
increasing enzyme active site occupancy. With compound 4 this 
minimum ratio was found to be 1.2:1. Therefore, 4 was added to 
ZR-75-1 cell extracts at a final concentration ranging from 
0.6 µM to 2.5 µM, but the signal-to-noise ratio was poor at these 
low concentrations and the λmax peak (at 585 nm) could not be 
detected. This confirmed the hypothesis that the potency and 
sensitivity of 4 must be increased in order to enable hNAT1 
detection in such cell extracts. 
 
2.2.  Overview of SAR Studies 
In this study we systematically varied substituents at the C2, 
C3 and C5-C8 positions of naphthoquinone 4, to improve our 
understanding of inhibitor-hNAT1 interactions which could 
guide the rational design of colorimetric probes for specific 
hNAT1 detection and inhibition (Figure 3). Synthesis of novel 
inhibitors, guided by in silico studies, sought to increase both the 
potency and absorption coefficients of the inhibitor, whilst 
retaining both selectivity for hNAT1 over hNAT2 and the ability 
to observe a distinctive color change in the presence of hNAT1. 
 
 
 
 
 
 
 
 
 
Figure 3: Structure-activity relationships investigated in this study. 
 
2.3. SAR at C3 of the Naphthoquinone Core 
2.3.1. C3 Amino-Substituted Analogues 
Initially, compounds 3, 4 and 6, which we have reported 
previously,23 were synthesized in a two-step procedure from 2,3-
dichloronaphthalene-1,4-dione 7 via successive addition-
elimination reactions (Scheme 1; Table 1). The reaction 
conditions were optimized from those previously reported23 
leading to improved overall yields (for optimization see 
Scheme S1 and Table S1 in Supporting Information).  
A small series of aliphatic amino groups were also introduced 
at the C3 position by substitution of chloride from intermediate 8 
with aliphatic amines. In comparison to anilines, aliphatic amines 
possess higher conformational freedom and are unable to form pi-
pi interactions within the NAT active site upon binding. A series 
of analogues was chosen to allow comparison of effects of chain 
extension, inclusion of polar heteroatoms and aromatic moieties 
(Scheme 1; Table 1). Their synthesis was analogous to that of 4 
except it was found that step (ii) proceeded in excellent yield 
within only 6 h in toluene. 
 
Scheme 1: Reagents and conditions: (i) PhSO2NH2 (1.0 eq.), Cs2CO3 
(1.4 eq.), DMF, RT, 5 h; (ii) either CeCl3.7H2O (1.0 eq.), MeOH, RT, 90 min. 
then requisite aniline (3.0 eq.), 110 °C, 16 h; or CeCl3.7H2O (1.0 eq.), 
toluene, RT, 90 min. then requisite amine (3.0 eq.), toluene, 110 °C, 6 h. 
 
Table 1. Identities of R2 substituents and yields for the amino 
analogue series. 
 
 
2.3.2. C3 Aryloxy-Substituted Analogues 
Aryloxy analogues of 4 were also synthesized, since these 
were predicted to have similar conformational preferences to 
anilino substituents whilst possessing H-bond acceptor but not 
donor ability. Initially, intermediate 8 was pre-treated with 
CeCl3.7H2O before addition to sodium phenoxide (generated by 
treatment of phenol with NaH) in toluene; however, none of the 
desired product was obtained (Scheme 2). A Buchwald-type 
cross-coupling reaction involving the bulky electron-rich ligand 
ditBuXPhos 12 between 8 and phenol was subsequently 
attempted,27 but returned only starting materials. The same 
Buchwald conditions applied to the dichloro precursor 7 yielded 
the monophenoxy-substituted derivative 13 in moderate yield. 
Subsequent treatment of 13 with CeCl3.7H2O and 
benzenesulfonamide, however, resulted in the sulfonamide 
displacing the phenoxy substituent rather than the desired 
chloride leading to formation of 8. Attempted cross-coupling 
between 13 and PhSO2NH2 with Pd(dppf)2Cl2 as a catalyst also 
afforded 8. 
Given the susceptibility of phenoxy substituents to 
displacement by benzenesulfonamide, an alternative route to 
aryloxy analogues of 4 via the corresponding diaryloxy 
naphthoquinones was developed. Dichloride 7 was treated with 
the requisite aryl alcohol and cesium carbonate in THF at reflux 
to give the corresponding diaryloxy-substituted naphthoquinones 
14-16, which were subsequently treated with 
benzenesulfonamide and cesium carbonate in THF at 80 °C for 1 
h. Recrystallisation from toluene gave the desired C3 aryloxy-
substituted analogues 17-19 (Scheme 2; Table 2). 
Compound R2 Yield of step (ii) 
3 Ph 63% 
4 3’’,5’’-Me2-C6H3 57% 
6 4’’-Br-C6H4 30% 
9 2’’-Methoxyethyl 87% 
10 Cyclopentyl 89% 
11 Benzyl 42%
 
O
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H
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NHR2
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H
N
Cl
S
O O
Ph S Ph
O O
O
O
Cl
Cl
(i) (ii)
7 8 3-4, 6, 9-11
94% 30-89%
  
 
Scheme 2: Reagents and conditions: (i) CeCl3.7H2O (1.0 eq.), toluene, 
RT, 90 min., then NaOPh (1.0 eq.), reflux, 16 h; (ii) PhOH (1.2 eq.), 
Pd(OAc)2 (0.02 eq.), 12 (0.03 eq.), K3PO4 (2.0 eq.), toluene, reflux, 16 h; 
(iii) CeCl3.7H2O (1.0 eq.), toluene, RT, 90 min., then PhSO2NH2 (3.0 eq.), 
reflux, 18 h; (iv) PhSO2NH2 (1.2 eq.), Pd(dppf)2Cl2 (0.02 eq.), Cs2CO3 
(2.0 eq.), dioxane, reflux, 1 h; (v) ArOH (2.2 eq.), Cs2CO3 (2.2 eq.), THF, 
reflux, 16 h; (vi), PhSO2NH2 (1.2 eq.), Cs2CO3 (1.2 eq.), THF, reflux, 1 h. 
 
Table 2: Identities of R2 substituents and yields for the 
aryloxy analogue series. 
 
 
2.3.3. C3 Aryl-Substituted Analogues  
A library of C3 aryl-substituted analogues, which are 
predicted to have different conformational preferences to the 
anilino derivatives and lack both H-bond donor and acceptor 
properties, was synthesized. Suzuki cross-coupling reactions of 
chloride 8 and the requisite boronic acid with Pd(PPh3)2Cl2 in 
4:1 THF:sat. aq. NaHCO3 proceeded in 70-80% yield; partial 
purification by column chromatography followed by 
recrystallisation from toluene led to isolation of analogues 20-26 
in moderate to low yield (Scheme 3; Table 3). 
 
 
 
Scheme 3: Reagents and conditions: (i) PhSO2NH2 (1.0 eq.), Cs2CO3 
(1.4 eq.), DMF, RT, 5 h; (ii) Requisite boronic acid (2.0 eq.), Pd(PPh3)2Cl2 
(0.1 eq.), 4:1 THF:sat. aq. NaHCO3, reflux, 18 h. 
 
 
 
Table 3: Identities of R2 substituents and yields for the aryl 
analogue series. 
 
 
2.3.4. Pharmacological Evaluation of the C3-Substituted 
Analogues 
All of the synthesized analogues of compound 4 were initially 
tested for inhibitory potency against recombinant mNat2 and 
hNAT1, which were expressed and purified as outlined in 
Section 4.2.1..22, 28 NAT activity in the presence of an inhibitor 
was determined by measuring the rate of acetyl coenzyme A 
(AcCoA) hydrolysis using a previously described method.29 The 
IC50 value of each synthesized compound is given in Table 4; 
squared correlation coefficients for these data are presented in 
Table S2 in Supporting Information. 
 
Table 4: IC50 values for the C3 analogue library. 
 
 
 
 
A wide variety of substituents appears to be tolerated at the 
C3 position, with examples of anilino, aryloxy and aryl groups at 
this position all exhibiting inhibition of hNAT1 and mNat2. This 
suggests that the N-H hydrogen bond donor capability of anilino-
substituted species such as 4 is not essential for binding to the 
enzyme, since ligands with hydrogen bond acceptor properties at 
C3 (aryloxy-substituted species such as 17) and ligands with 
Compound R2 Isolated Yield step (v) 
Isolated Yield 
step (vi) 
17 Ph 63% 67% 
18 3’’,5’’-Me2-C6H3 89% 57% 
19 4’’-Br-C6H4 72% 43% 
Compound R2 Isolated Yield step (ii) 
20 2’’-Cl-C6H4 48% 
21 3’’-Cl-C6H4 35% 
22 4’’-Cl-C6H4 47% 
23 3’’-CHO-C6H4 31% 
24 4’’-CHO-C6H4 24% 
25 2’’-furanyl 45% 
26 3’’-furanyl 23% 
Compound R2 IC50 (mNat2) (µM) 
IC50 (hNAT1) 
(µM) 
3 NHPh 1.923 1.723 
4 NH-3’’,5’’-Me2-C6H3 2.4 4.1 
6 NH-4’’-Br-C6H4 1.7 0.9 
9 NHCH2CH2OMe > 30 > 30 
10 NH-Cyclopentyl > 30 > 30 
11 NHCH2Ph > 30 > 30 
17 OPh 1.8 2.8 
18 O-3’’,5’’-Me2-C6H3 5.2 12.1 
19 O-4’’-Br-C6H4 1.1 1.9 
20 2’’-Cl-C6H4 3.7 8.0 
21 3’’-Cl-C6H4 5.1 14.5 
22 4’’-Cl-C6H4 8.2 12.1 
23 3’’-CHO-C6H4 9.2 8.4 
24 4’’-CHO-C6H4 6.9 10.3 
25 Furan-2’’-yl 4.3 9.6 
26 Furan-3’’-yl 1.4 10.0 
R2
O
O
H
N
S
Ph
O O
  
neither hydrogen-bond-acceptor nor -donor properties at C3 (aryl-
substituted species such as 26) bind with similar potencies to that 
of compound 4. In silico modeling was carried out on compounds 
3, 4, 6 and 17-26 and suggests that the binding modes of all the 
anilino-, aryloxy- and aryl-substituted species are similar, 
supporting the experimental observations; representative 
examples of modeling solutions are shown in Figure 4(a). 
The other key observation from the pharmacological data is 
that all derivatives bearing an aliphatic substituent at C3 (9-11) 
display poor levels of inhibition vs. hNAT1 and mNat2. Docking 
suggests that no residues around the entrance to the active site are 
capable of forming pi-pi interactions with the C3 moiety; however, 
any of the conformational preferences, electronic properties or 
hydrophobicity of aromatic substituents may be a requisite of 
binding (Figure 4(b)). Examples of both electron-rich and 
electron-poor aromatic moieties at C3 have shown similar levels 
of potency to the hit compound 4.  
 
 
Figure 4: (a) In silico modeling of representative compounds 4 (carbons 
in grey), 17 (carbons in cyan) and 26 (carbons in yellow) in the active site of 
hNAT1 (pdb: 2PQT)12e. (b) Surface-filled model for interaction of compound 
4 with hNAT1, depicting electrostatic surfaces and illustrating the active site 
pocket. Analysis performed using GOLD® software.30 
 
The ground state rotational freedom of amino-substituted 
species 9 and 11 and the concomitant loss of entropy on binding 
to hNAT1 could also contribute to the low inhibitory potency of 
these compounds. However, the less conformationally flexible 
cyclopentylamine 10 is also a poor inhibitor, suggesting that an 
N-, O-, or directly linked aromatic substituent is indeed preferred 
at the C3 position. 
 
2.3.5. Spectrophotometric Evaluation of the C3-Substituted 
Analogues 
For a probe to be clinically useful for quantification of 
hNAT1 in biological samples, it not only needs to be a potent and 
selective binder of hNAT1, but it must also possess appropriate 
colorimetric properties, namely: the probe must have a pKa value 
for the acidic sulfonamide proton above the assay pH of 8 but 
below the pKaH of the Arg127 residue; the color change should 
be distinct, so that it can be unambiguously determined from 
visible spectra; and the conjugate base of the probe must have a 
high absorption coefficient (εCB) to enable a high sensitivity of 
detection. 
The colorimetric properties of species 3, 4, 6, 9-11 and 17-26 
were evaluated and are outlined in Tables 5 and 6. pKa values 
were determined via titration experiments (outlined in Section 
4.2.4.2.). ε Values for both the neutral (εN) and conjugate base 
(εCB) forms of each compound were calculated following the 
experimental procedure described in Section 4.2.4.3.. 
Despite the promising inhibitory potency of both the C3 
aryloxy- and aryl-substituted species, the utility of both of these 
series of compounds as colorimetric probes are limited by their 
low pKa values, which are below that of physiological pH. 
Conversely, all the anilino-substituted and amino-substituted 
species synthesised show clear changes in λmax between pH 8 and 
pH 13. The anilino-substituted species 3, 4 and 6 also show a 
color change in the presence of mNat2, whereas the amino-
substituted species 9-11 do not; this is likely to be attributable to 
the weak binding of the amino-substituted species against the 
enzyme (IC50 > 30 µM). However, none of the conjugate bases 
display significantly enhanced absorption coefficient values over 
that of the conjugate base of 4. 
Therefore, attention was next turned to modifying the 
substituent at the C2 position on the naphthoquinone core instead.
 
 
Table 5: pKa values for the C3 library of inhibitors. 
 
 
 
Table 6: Spectrophotometric properties of the anilino- and amino-substituted inhibitors 3, 4, 6 and 9-11. N.D. = not determined. 
 
 
Compound 3
 
4 6 9 10 11 17 18 19 20 21 22 23 24 25 26 
pKa 9.5 9.2 10.4 9.8 10.1 10.4 5.0 5.0 5.0 4.9 4.5 5.0 5.0 4.6 5.1 5.0 
Compound R2 Compound 
at pH 8 
Compound 
at pH 13 
∆λmax pH 13 
(nm) 
∆λmax mNat2 
(nm) 
εCB (M-1cm-1) εCB / εCB(4) 
3 NHPh 
 
 
+ 71 + 121 7900 1.20 
4 NH-3’’,5’’-Me2-C6H3 
 
 
+ 79 + 112 6590 1.00 
6 NH-4’’-Br-C6H4 
 
 
+ 70 + 93 7790 1.18 
9 NHCH2CH2OMe 
 
 
+ 89 N.D. 1010 0.15 
10 NH-Cyclopentyl 
 
 
+ 82 + 3 4470 0.68 
11 NHCH2Ph 
 
 
+ 74 + 5 5770 0.88 
  
2.4. SAR at C2 of the Naphthoquinone Core 
2.4.1. C2 Sulfonamido-Substituted Species 
In silico docking of compounds 48 and 49 in hNAT1 as 
representative examples of new analogues suggested that at the 
C2 position, there are key interactions between the sulfonamide 
group and Arg127 (a hypothesis supported by our previous 
work)21 and between the R1 substituent and Tyr129 (Figure 5). 
This potential interaction was investigated by synthesis of a 
library of analogues of 4 containing examples of both aliphatic 
and aromatic R1 substituents (Scheme 4; Table 7). All 
sulfonamides were commercially available except for 29 and 30, 
which were prepared from the corresponding sulfonyl chlorides 
using standard methods.31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: In silico modeling of 48 and 49 in the active site of hNAT1 
(pdb: 2PQT)12e, highlighting the potentially key interactions between the 
inhibitors and enzyme. Distances between atoms highlighted by black dashed 
lines are given in Angstroms. Analysis performed using GOLD® software.30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4: Reagents and conditions: (i) NH3 (aq., 33%), RT, 30-
100 min.; (ii) requisite sulfonamide (1.0 eq.), Cs2CO3 (1.4 eq.), DMF, RT, 5-
16 h; (iii) CeCl3.7H2O (1.0 eq.), MeOH, RT, 90 min., then 3,5-
dimethylaniline (3.0 eq.), 90 °C, 16 h. 
 
Table 7: Identities of R1 and yields for the C2 sulfonamide 
library. 
 
 
Figure 6: The % residual activity of mNat2 and hNAT1 when dosed with 
30 µM of compounds 4 and 41-50. Experiments were conducted in triplicate 
and results are shown as averages ± one standard deviation. The stars and 
brackets above the bars show the significance of the difference between the 
mNat2 and hNAT1 data when a Student’s T-Test was performed: no stars = 
P > 0.05; * = P < 0.05; ** = P < 0.01; *** = P < 0.001. 
 
An analysis of the potency of these compounds against 
hNAT1 and mNat2 (Figure 6) shows that many of these 
compounds are poor inhibitors of both enzymes. IC50 values were 
subsequently determined for species showing > 50% inhibition at 
30 µM. The only compounds in this series which display 
comparable potency to phenyl-substituted 4 against one or both 
proteins are the bioisosteric 4’-fluorophenyl-substituted 48 
(IC50, mNat2 = 3.9 µM; IC50, hNAT1 = > 30 µM), 2’,6’-difluorophenyl-
substituted 45 (IC50, mNat2 = 10.0 µM; IC50, hNAT1 = 10.0 µM) and 
furan-2’-yl-substituted 49 (IC50, mNat2 = 1.9 µM; IC50, hNAT1 = 
7.0 µM). 2’-methylphenyl-substituted 43 and 2’-nitrophenyl-
substituted 44 show weak activity with IC50 values against 
hNAT1 of 23.1 µM and 21.8 µM respectively. 
First, these results suggest that at the C2 position, an aryl or 
heteroaryl substituent appears to be required for binding to 
hNAT1; compound 42, which incorporates a fully saturated 
analogue of the phenyl group within 4, shows poor levels of 
hNAT1 and mNat2 inhibition. This is possibly because pi-pi 
interactions are instrumental in achieving high inhibitor potency, 
a conclusion which supports the binding mode predicted by in 
silico modeling (Figure 5) which suggests an interaction between 
an aromatic C2 substituent and the Tyr129 residue of hNAT1. 
Compound R1 Isolated Yield Step (ii) 
Isolated Yield 
Step (iii) 
4 Ph 91% 57% 
41 Me 39% 65% 
42 cHex 64% 32% 
43 2’-Me-C6H4 70% 49% 
44 2’-NO2-C6H4 44% 20% 
45 2’,6’-F2-C6H3 67% 33% 
46 3’-NO2-C6H4 Quant. 26% 
47 4’-Me-C6H4 66% 25% 
48 4’-F-C6H4 63% 59% 
49 Furan-2’-yl 85% 66% 
50 Benzyl 81% 53% 
(iii)
O
O
H
N
NH
O
O
H
N
ClCl
O
O
Cl
(ii) S
O O
R1
S
R1
O O
Cl
S
R1
O O
H2N
S
R1
O O
(i)
R1 = chex (27)
2-furyl (28)
R1 =
chex (29) 91%
2-furyl (30) quant.
7 8, 31-40 4, 41-50
  
Table 8: Spectrophotometric properties of the C2 sulfonamide-substituted inhibitors 4 and 41-50. N.D. = not determined. 
 
 
Furthermore, the results show that substitution on the 
aromatic R1 moiety is poorly tolerated, with examples of both 
electron-donating and electron-withdrawing ortho-, meta- and 
para- substituted species showing poor levels of inhibition. The 
only substitution tolerated on an aromatic R1 moiety was found to 
be fluoro substitution (compounds 45 and 48), which suggests 
that the R1 aromatic group occupies a tight pocket within the 
enzyme active site. This hypothesis was further supported by the 
synthesis of the benzyl substituted analogue 50, which also 
shows much poorer levels of inhibition than 4. 
The importance of the Tyr129 residue of hNAT1/mNat2 in 
binding of these naphthoquinone ligands was further investigated 
in a study on the homologous enzyme from the Syrian hamster, 
shNat2. hNAT1 and shNat2 share an 81% sequence homology 
and homology in substrate specificity,32 but in shNat2, Tyr129 is 
replaced by Leu (see Figure S1 in Supporting Information for 
sequence alignment). Other key active site residues, in particular 
Arg127, Phe125 and the catalytic Cys-His-Asp triad, are 
conserved between shNat2, hNAT1 and mNat2. Compound 4 
was found to be a poor inhibitor of shNat2 (IC50 = 89 µM) 
although some evidence of a color change was observed upon 
binding; this suggests that Tyr129 does indeed play a crucial role 
in inhibitor recognition. 
The colorimetric properties of this series of inhibitors were 
also evaluated (Table 8). Varying the R1 substituent appears to 
have little effect on the λmax value of the neutral species; 
however, electron-donating or electron-withdrawing groups can 
have a significant effect on both the pKa and εCB of the inhibitor. 
Inhibitors with lower pKa values (close to 8) are unsurprisingly 
found to exhibit smaller shifts in λmax in the presence of either 
base or enzyme relative to λmax at pH 8. 2’,6’-Difluorophenyl- 
and 2-furyl-substituted species 45 and 49 have undesirably low 
pKa values (and hence ∆λmax), despite showing improved εCB 
values and similar potencies to those of the hit compound 4. 
 
 
2.4.2. C2 Amido-Substituted Species 
On the basis of the in silico studies carried out (Figures 4 
and 5), which was supported by and consistent with our initial 
SAR data, we hypothesised that an amide group might be a 
suitable alternative to the sulfonamide as a binding partner for the 
guanidinium group of Arg127. An amide group would be 
expected to have a different preferred conformation to a 
sulfonamide group,33 which is likely to affect the binding to 
hNAT1. Replacement of the sulfonamide functionality might also 
be expected to alter the colorimetric properties of the molecules, 
such as λmax and ε values. It was also anticipated the sulfonamide 
to amide switch would increase the pKa by ~7-8 log units.34 Since 
amides have shorter bond lengths than their sulfonamide 
counterparts,35 it was predicted that a larger R1 substituent than 
phenyl might be required to retain the important pi-pi interactions 
in the binding site; in particular, computational modeling studies 
support the proposal of a benzyl amide substituent as an isostere 
for a phenyl sulfonamide substitutent (see Figure S2 in 
Supporting Information). 
Initially, a library of amides bearing a 3,5-dimethylanilino 
group at C3 were synthesized for direct comparison with hit 
compound 4. Literature procedures to generate the known 
intermediates 52 and 53 were followed (Scheme 5).36 However, 
the attempted synthesis of 54 proceeded in low yield and thus a 
general coupling procedure to access these intermediates was 
developed, using the conversion of 51 to 54 as the model reaction 
(see Scheme S2 and Table S2 in Supporting Information). The 
optimum conditions were found to involve Lewis acid catalysis 
with BF3.OEt2 in toluene; these improved conditions were 
subsequently used to synthesize intermediates 54, 55 and 58 in 
good yield. From intermediates 52, 54, 55 and 58, the desired 
final products could be obtained by substitution with 3,5-
dimethylaniline (under our standard conditions); however 
intermediate 53 was inert under these reaction conditions. Final 
product 60 was therefore obtained using a Buchwald-Hartwig 
coupling between naphthoquinone intermediate 53 and 3,5-
dimethylaniline.37 
Compound R1 pKa Compound at pH 8 
Compound 
at pH 13 
∆λmax pH 13 
(nm) 
∆λmax mNat2 
(nm) εCB (M
-1cm-1) εCB / εCB(4) 
4 Ph 9.2 
 
 
+ 79 + 112 6590 1.00 
41 Me 9.5 
  
+ 87 N.D. 6770 1.03 
42 cHex 10.6 
 
 
+ 53 - 7 6790 1.03 
43 2’-Me-C6H4 9.3 
  
+ 17 N.D. 6430 0.98 
44 2’-NO2-C6H4 7.9 
  
+ 32 N.D. 7610 1.16 
45 2’,6’-F2-C6H3 8.4 
 
 
+ 39 + 79 7780 1.18 
46 3’-NO2-C6H4 8.6 
 
 
+ 42 N.D. 5670 0.86 
47 4’-Me-C6H4 9.7 
  
+ 73 - 8 7170 1.09 
48 4’-F-C6H4 9.9 
 
 
+ 59 + 122 3490 0.53 
49 Furan-2’-yl 8.3 
 
 
+ 32 + 99 7770 1.18 
50 Benzyl 10.0 
 
 
+ 61 + 57 6660 1.01 
  
The SAR at C2 for the amide series is steep, with only the 
benzyl amide 61 showing a moderate level of mNat2 inhibition 
(IC50, mNat2 = 28.1 µM), and all of the series have IC50 values of  
> 30 µM against hNAT1 (Figure 7). The inactivity of phenyl 
amide 60 is possibly attributable to the restricted rotation 
imposed on the molecule through the use of the amide linker, 
which might prevent the key pi-pi interactions with Tyr129 
between the aryl rings from forming. Introduction of a flexible    
–CH2– linker in benzyl amide 61 while improving inhibitory 
activity still however does not lead to levels of potency which are 
equivalent to sulfonamide 4. 
 
Scheme 5: Reagents and conditions: (i) MeCOCl (excess), c. H2SO4 
(cat.), 50 °C, 1 h; (ii) NaH (3.3 eq.), THF, RT, 30 min. then PhCOCl 
(1.3 eq.), RT, 1 h; (iii) requisite acyl chloride (4.0 eq.), BF3.OEt2 (1.0 eq.), 
toluene, 90 °C, 4 h; (iv) CeCl3.7H2O (1.0 eq.), MeOH, RT, 90 min. then 3,5-
dimethylaniline (3.0 eq.), 110 °C, 16 h; (v) 3,5-dimethylaniline (1.2 eq.), 
Pd(OAc)2 (0.01 eq.), XPhos (0.03 eq.), K2CO3 (1.4 eq.), H2O (0.04 eq.), 
tBuOH, 100 °C, 16 h; (vi) (COCl)2 (1.2 eq.), DMF, CH2Cl2, RT, 3 h; (vii) 
naphthoquinone 51 (0.25 eq.), BF3.OEt2 (0.25 eq.), toluene, 90 °C, 4 h.  
 
Figure 7: The % residual activity of mNat2 and hNAT1 when dosed 
with 30 µM of compounds 59-63. Experiments were conducted in triplicate 
and results are shown as averages ± one standard deviation. The stars and 
brackets above the bars show the significance of the difference between the 
mNat2 and hNAT1 data when a Student’s T-Test was performed: no stars = 
P > 0.05; * = P < 0.05; ** = P < 0.01; *** = P < 0.001. 
One alternative explanation for the lack of activity of these 
amides is that all of these species 59-63 possess pKa values 
higher than 14, which is likely to preclude formation of their 
conjugate bases in the presence of hNAT1/mNat2 in an assay 
buffer of pH 8. We have previously established that the color 
change of sulfonamide inhibitors such as 4 in the hNAT1 active 
site is due to selective recognition of the conjugate base species 
by the enzyme.21 If hNAT1 and mNat2 were to have higher 
affinities for the conjugate base species of any given 
naphthoquinone inhibitor than the respective neutral species, then 
one might expect naphthoquinones with very high pKa values to 
be poor inhibitors. 
Therefore, a small number of species with an amide 
substituent at C2 but with an aryl substituent replacing the aniline 
substituent at C3 were synthesized, to test the inhibitory potency 
and colorimetric properties of amides with pKa values predicted 
to be within a more appropriate range. These species were 
synthesized via a Suzuki coupling reaction (Scheme 6; Table 9). 
 
 
 
 
 
 
 
 
 
Scheme 6: Reagents and conditions: (i) Requisite boronic acid (2.0 eq.), 
Pd(PPh3)2Cl2 (0.1 eq.), 4:1 THF:sat. aq. NaHCO3, reflux, 18 h. For identities 
of R1 and R2, refer to Table 9. 
 
Table 9: Yields in the synthesis of amides 64-67. 
 
Table 10: Pharmacological and spectrophotometric properties 
of amides 64-67. 
 
This small series of amide compounds were indeed found to 
have lower pKa values than their C3 anilino-substituted 
counterparts (Table 10). Furthermore, all examples displayed 
Compound R1 R2 Isolated Yield step (i) 
64 Ph 3’’-CHO-C6H4 15% 
65 Ph Furan-3’’-yl 
 
59% 
66 Bn 3’’-CHO-C6H4 44% 
67 Bn Furan-3’’-yl 
 
9% 
Compound 64
 
65 66 67 
IC50 (mNat2) 
(µM) 
30.4 14.5 36.8 23.5 
IC50 (hNAT1) 
(µM) 
10.0 19.0 22.1 19.3 
pKa 10.9 12.1 11.4 12.5 
Compound at 
pH 8 
 
 
 
 
Compound at 
pH 13
 
 
 
 
 
λmax shift at 
pH 13? 
Yes Yes Yes Yes 
λmax shift with 
mNat2? 
Yes No No No 
εCB (M-1cm-1) 2672 4817 8491 2449 
εCB / εCB(4) 0.41 0.73 1.29 0.37 
  
improved IC50 values against hNAT1 relative to the analogues 
with an anilino substituent at C3. This supports a potential link 
between pKa and potency which is currently under further 
investigation. The compound in this series with the lowest pKa 
value, 64, is shown to undergo a shift of λmax in the presence of 
enzyme (Figure 8). Compounds 65, 66 and 67 do not show 
corresponding ∆λmax shifts; this could be due to their higher pKa 
values or because they have a different binding mode in the 
enzyme active site; in silico modeling does propose a feasible 
alternative mode of binding for the furanyl-substituted species 65 
in which the furanyl oxygen is capable of binding to Arg127 in 
place of the amide carbonyl oxygen (Figure 9), which would 
preclude a color change driven by recognition between the 
conjugate base and Arg127. 
Whilst studies on these compounds give an interesting 
mechanistic insight into molecular interactions with the enzyme 
active site, colorimetric studies show that they suffer from lower 
εCB values than the corresponding sulfonamides (Table 10). 
Furthermore, when tested against hNAT2, it was found that 
amide species 64 and 65 were far less selective for hNAT1 over 
hNAT2 than their sulfonamide analogues, with 64 and 65 
showing > 50% inhibition of hNAT2 at 30 µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Visible spectra of compound 64 (left) and 65 (right), showing 
the compounds at a final concentration of 15 µM in 20 mM Tris.HCl buffer 
solution, pH 8 (yellow line), 4 M NaOH solution, pH 13.75 (purple line) and 
in 20 mM Tris.HCl buffer solution, pH 8, with 30 µM mNat2 (blue line). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: In silico modeling of 65 in the active site of hNAT1 (pdb: 
2PQT)12e, highlighting a potential alternative binding mode for this furanyl 
analogue. Distances between atoms highlighted by black dashed lines are 
given in Angstroms. Analysis performed using GOLD® software.30 Docking 
was repeated 10 times giving consistent results. 
 
2.5. SAR at C5-C8 of the Naphthoquinone Core 
Since the sulfonamide inhibitors generally appear to have 
more favorable properties than their amide analogues, a series of 
nitro- and amino-substituted species at the C5-C8 positions was 
synthesized via a similar preparation to 4 but starting from 5- or 
6-nitro-2,3-dichloronaphtho-1,4-quinone 68 or 69, and utilizing 
10% Pd on carbon as a catalyst for the reduction in the final step 
(Schemes 7 and 8). It was also thought that the introduction of 
substituents at the 5-, 6-, 7- or 8-positions might allow 
exploitation of new inhibitor-enzyme interactions, which could 
lead to an increase in inhibitory potency against hNAT1. In silico 
modeling studies suggest that amino substituents at the 7- or 8-
positions may be able to interact with the backbone carbonyls of 
residues Gly124 or Phe125 (Figure 10); conversely it was 
hypothesized that nitro substituents at these positions might not 
be tolerated. Docking did not reveal any obvious additional polar 
contacts which might be gained by substitution at the 5- or 6-
positions. 
In addition, it was hypothesized that amino substitution could 
increase the absorption coefficient, ε, of the ligands relative to 
that of the unsubstituted species 4, since the amino group is 
auxochromic and could donate electron density into the 
naphthoquinone core. 
 
Figure 10: In silico modeling of 81 (carbons in grey) and 82 (carbons in 
cyan) in the active site of hNAT1 (pdb: 2PQT)12e, highlighting potential 
interactions between the 7- or 8-amino substituent and the backbone 
carbonyl oxygen of Gly124 or Phe125. Distances between atoms highlighted 
by red dashed lines are given in Angstroms. Analysis performed using 
GOLD® software.30 
 
When substituents were introduced directly onto the 
naphthoquinone core at positions 5-8, some clear SAR patterns 
emerged. A 5-nitro substituent (74) displayed similar IC50 values 
to those of compound 4 against hNAT1 and mNat2, whilst those 
with 6-nitro, 7-nitro or 8-nitro substituents (75-77) were 
significantly less active (Table 11; for squared correlation 
coefficients for IC50 data see Table S2 in Supporting 
Information). For the amino-substituted series, 5-amino 
derivative 79 and 7-amino derivative 81 had potencies 
comparable to that of 4, whilst the 6-amino derivative 80 showed 
low potency and the 8-amino derivative 82 possessed IC50 values 
one order of magnitude more potent than 4. These experimental 
results correlate well with the predictions from in silico 
modeling. 
Given the high potency of compound 82 against both hNAT1 
and mNat2, with IC50 values of 540 nM and 430 nM respectively 
against each enzyme, the analogous species 83 was also 
synthesized. With IC50 values against hNAT1 and mNat2 of 120 
and 270 nM respectively, 83 represents the most potent inhibitor 
of hNAT1 and mNat2 synthesized in this study. Its nitro-
substituted precursor 78 had low activity (> 30 µM) against both 
enzymes. 
Crucially, both 8-amino substituted species 82 and 83 possess 
significantly improved absorption coefficients compared to 
compound 4, whilst still leading to a discernible color change in 
the presence of mNat2; compound 82 was also found to be highly 
selective for hNAT1 and mNat2 over hNAT2 (Table 11; Figure 
11). Compounds 82 and 83 were therefore subjected to further 
studies in lysates from ZR-75-1 cells. 
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Scheme 7: Reagents and conditions: (i) PhSO2NH2 (1.0 eq.), Cs2CO3 (1.4 eq.), DMF, RT, 5 h; (ii) CeCl3.7H2O (1.0 eq.), MeOH, RT, 90 min. then requisite 
aniline (3.0 eq.), 110 °C, 16 h; (iii) Pd/C 10% (0.1 eq.), H2, MeOH, RT, 16 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8: Reagents and conditions: (i) PhSO2NH2 (1.0 eq.), Cs2CO3 (1.4 eq.), DMF, RT, 5 h; (ii) CeCl3.7H2O (1.0 eq.), MeOH, RT, 90 min. then requisite 
aniline (3.0 eq.), 110 °C, 16 h; (iii) Pd/C 10% (0.1 eq.), H2, MeOH, RT, 16 h. 
 
Table 11: Pharmacological and spectrophotometric properties of nitro- and amino-substituted naphthoquinones 74-83. N.D. = 
not determined. *Not possible to determine pKa via this method. 
 
Compound 
IC50 
(mNat2) 
(µM) 
IC50 
(hNAT1) 
(µM) 
Compound 
at pH 8 
Compound 
at pH 13 
∆λmax pH 13 
(nm) 
∆λmax mNat2 
(nm) pKa εCB εCB/ εCB(4) 
74 2.7 6.6 
  
+ 23 + 95 8.2 4517 0.69 
75 > 30 > 30 
 
 
+ 73 + 74 7.5 2241 0.34 
76 > 30 N.D. 
 
 
+ 87 N.D. 8.0 3879 0.59 
77 > 30
 
> 30 
  
+ 58 N.D. 8.6 2737 0.42 
78 > 30 > 30 
 
 
+ 74 + 107 8.4 3012 0.46 
79 5.7 4.2 
  
+ 16 + 16 * 15796 2.40 
80 > 30 N.D. 
  
- 9 N.D. * 12542 1.90 
81 2.5 2.6 
  
+10 0 * 21892 3.32 
82 0.43 0.54 
 
 
- 63 - 62 8.4 12384 1.88 
83 0.27 0.12 
  
- 28 - 12 8.2 15842 2.40 
  
 
Figure 11: The % residual activity of mNat2, hNAT1 and hNAT2 when 
dosed with compounds 74, 77, 79 and 82 at 30 µM. Hit compound 4 is also 
included as a control. Experiments were conducted in triplicate and results are 
shown as averages ± one standard deviation. The stars and brackets above the 
bars show the significance of the difference between pairs of data when a 
Student’s T-Test was performed: no stars = P > 0.05; * = P < 0.05; ** = 
P < 0.01; *** = P < 0.001. 
 
2.6. Evaluation in Cell Extracts from the Breast Cancer Cell 
Line ZR-75-1 
Representative compounds from this study possessing a range 
of functionality were tested for inhibitory activity of hNAT1 in 
ZR-75-1 lysate at concentrations of 30 µM, 10 µM and 1 µM 
(Figure 12). All the representative sulfonamides which showed 
high levels of potency against recombinant hNAT1 also showed 
high levels of inhibition against hNAT1 in the lysate, with 
compounds 4, 48, 81 and 82 exhibiting > 50% inhibition of 
hNAT1 at an inhibitor concentration of 1 µM. 
 
Figure 12: The % residual activity of hNAT1 in ZR-75-1 cell lysate 
when dosed with representative compounds 3, 4, 45, 48, 49, 77, 81 and 82 at 
30 µM, 10 µM and 1 µM, relative to a control experiment (vehicle only). 
Experiments were conducted in triplicate and results are shown as averages ± 
one standard deviation. The stars above the bars show the significance of the 
difference between the test data and its respective control when a Student’s T-
Test was performed: no stars = P > 0.05; * = P < 0.05; ** = P < 0.01; *** = 
P < 0.001. 
 
8-amino substituted species 82 and 83 possessing a tenfold 
and fiftyfold improved potency against hNAT1 over 4 
respectively, and with twofold improved εCB, were subsequently 
examined in spectrophotometric experiments with the ZR-75-1 
cell extracts in an attempt to detect the hNAT1 present in the 
cells. The probes were tested at final concentrations ranging from 
0.6 µM to 2.5 µM, but again due to poor signal-to-noise ratios no 
λmax peak could be detected at these low concentrations. A 
negative control concentration of 20 µM was also used, clearly 
showing λmax corresponding to the neutral (protonated) species in 
each case. This demonstrates that further improvements to the 
sensitivity of the probes are required for their clinical use; 
however, this study has provided key underpinning insights to 
demonstrate that there is a scope for variation around the 
naphthoquinone core of the original hit compound 5 in order to 
achieve this. 
3. Conclusions and Future Work 
In this study, we have designed and synthesized a family of 
naphthoquinones which are capable of rapidly and 
unambiguously detecting pure recombinant hNAT1 as they 
change color in the presence of the protein through a mechanism 
which we have previously elucidated. As no similar colorimetric 
probes have been reported to date in the literature, it proved 
necessary to determine the key requirements for such probes to 
be clinically useful. This study verifies that the potency, pKa and 
absorption coefficient of the conjugate base (εCB) are crucial 
parameters of probe design. We have developed extensive SAR 
around the naphthoquinone core of our hit compound 4, and have 
built up an in silico docking model which is consistent with our 
experimental observations; this should prove valuable for any 
future attempts to develop hNAT1 inhibitors and is summarized 
in Figure 13. Compounds 82 and 83 show ten- and fifty-fold 
increases respectively in potency and a two-fold increase in εCB 
over initial hit compound 4; 82 is also shown to retain selectivity 
for hNAT1 over its isoenzyme hNAT2. Although the conjugate 
bases of 82 and 83 could not be clearly detected in absorption 
spectra with ZR-75-1 extracts, they offer promising insights 
which aid ongoing work focused on increasing the εCB of these 
probes whilst retaining high potency and selectivity for hNAT1. 
The high potency of representative examples of the sulfonamide 
probes against hNAT1 in ZR-75-1 cell extracts also pave the way 
for the development of inhibitors with improved physical 
properties such as solubility and cell permeability which could 
potentially act as tools for elucidating the currently unknown role 
which hNAT1 plays in ER+ breast cancer progression; these 
studies are also ongoing. Such selective inhibitors of hNAT1 
with appropriate proerties for application in vivo might also 
possess a valuable therapeutic use. 
 
Figure 13: Summary of SAR elucidated around the naphthoquinone core 
of hit compound 4 in this study. 
4. Experimental 
4.1. Chemistry 
4.1.1. General Experimental 
Chemicals were purchased from Sigma-Aldrich UK, TCI UK, 
Apollo Scientific UK, Alfa Aesar UK, Fluorochem UK or Fisher 
Scientific UK and used without further purification. Where 
appropriate, all reactions involving moisture-sensitive reagents 
were carried out under a nitrogen or argon atmosphere using 
standard vacuum line techniques and glassware that was flame-
dried before use. Anhydrous DMF, anhydrous MeOH and 
anhydrous dioxane were purchased from Sigma-Aldrich UK in 
  
SureSealTM bottles and used without further purification; other 
anhydrous solvents were dried following the procedure outlined 
by Grubbs and co-workers.38 Water was purified by an Elix® UV-
10 system. Organic layers were dried over anhydrous MgSO4. 
Brine refers to a saturated aqueous solution of sodium chloride. 
In vacuo refers to the use of a rotary evaporator attached to a 
diaphragm pump. Pet ether refers to the fraction of petroleum 
spirit boiling between 30 and 40 °C. Thin layer chromatography 
was performed on Merck silica gel 60 F254 aluminium-supported 
thin layer chromatography sheets. Plates were visualised using 
UV light (254 nm), or thermal development after dipping in 1% 
aq. KMnO4. Flash column chromatography was performed on 
Kieselgel 60 silica in a glass column, or on a Biotage SP4 flash 
column chromatography platform. 
Melting points were recorded on a Gallenkamp Hot Stage 
apparatus and are uncorrected. Where relevant, the 
recrystallisation solvent is reported in parentheses. Infrared 
spectra were recorded on a Bruker Tensor 27 FT-IR 
spectrometer, neat or as KBr discs. Selected characteristic peaks 
are reported in wavenumbers (cm-1). NMR spectra were recorded 
on Bruker Avance spectrometers (DPX400, DQX400, AVII 500 
or DRX500) in the deuterated solvent stated.  The field was 
locked by external referencing to the relevant deuteron 
resonance.  Chemical shifts (δ) are reported in parts per million 
(ppm) and coupling constants (J) are quoted in Hz; both are 
reported to one decimal place. The coupling constants were 
determined by analysis using ACD Labs software. Low-
resolution mass spectra were recorded on either a VG MassLab 
20-250 or a Micromass Platform 1 spectrometer, operating in 
positive or negative mode, from solutions of MeOH. Accurate 
mass measurements were run on either a Bruker MicroTOF 
internally calibrated with polyalanine, or a Micromass GCT 
instrument fitted with a Scientific Glass Instruments BPX5 
column (15 m × 0.25 mm) using amyl acetate as a lock mass, by 
the mass spectrometry department of the Chemistry Research 
Laboratory, University of Oxford, UK. m/z Values are reported in 
Daltons and followed by their percentage abundance in 
parentheses. 
Reverse-phase high-performance liquid chromatography (RP-
HPLC) was performed by one of two methods, as stated. Method 
A: RP-HPLC was performed using a 1525 pump, 2707 
autosampler and 2849 detector, all from Waters. Separations 
were performed on a Phenomonex Luma C18 (analytical) column 
(5 µm particle size, 250.0 mm x 4.6 mm). Experiments were 
performed under gradient elution (eluent H2O containing 0.1% 
(v/v) TFA:MeCN 95:5 to 5:95 over 20 min. then isocratic for 
15 min.). Sample injections consisted of 40 µL of 2 mg/mL 
sample solution in MeCN. The flow rate was 1 mL/min. and 
detection was at a wavelength of 215 nm. Method B: RP-HPLC 
was performed on a Gilson instrument equipped with Gilson 306 
pumps, a Gilson 811C dynamic mixer, a Gilson 806 manometric 
module with automated sample injection on a Gilson 215 Liquid 
Handler, configured with a Gilson 819 valve actuator. 
Separations were performed on a Varian Omnisphere 5 C18 
(analytical) column (5 µm particle size, 150.0 mm x 4.6 mm). 
Experiments were performed under gradient elution (eluent H2O 
containing 0.1% (v/v) TFA:MeCN 95:5 to 5:95 over 8 min. then 
isocratic for 4 min.). Sample injections consisted of 20 µL of 
1 mg/mL sample solution in DMSO. The flow rate was 
1 mL/min. Detection was at wavelengths of 220 and 254 nm 
using a Gilson 170 Diode Array Detector. For each compound, 
retention times (tR) are quoted to the nearest minute and are 
followed by the % purity. 
Compounds are characterized throughout this experimental 
section by numbering aromatic carbons and any attached 
hydrogen nuclei as shown in Figure 14. 
 
 
 
 
 
 
 
 
Figure 14: Numbering system employed throughout based on a generic 
representative naphthoquinone species. 
 
4.1.2. Representative Procedures 
4.1.2.1. Representative Procedure 1: Substitution of 2,3-
dichloronaphthalene-1,4-diones with sulfonamides. 2,3-
Dichloronaphthalene-1,4-dione (1.0 eq.), the requisite 
sulfonamide (1.0 eq.) and Cs2CO3 (1.4 eq.) were stirred in DMF 
in a sealed microwave vial at RT for 5 h. 1 M aq. HCl (50 mL) 
was added and the organic product extracted with EtOAc (3 x 
20 mL). The organic washings were combined, washed with 
brine (3 x 20 mL), dried over magnesium sulfate, filtered and 
concentrated in vacuo to give the crude product. 
4.1.2.2. Representative Procedure 2: Substitution of N-(3-
chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)sulfonamides 
with anilines. The requisite sulfonamide (1.0 eq.) was stirred 
with cerium trichloride heptahydrate (1.0 eq.) in MeOH at RT in 
a microwave vial for 1.5 h. The requisite aniline (3.0 eq.) was 
added, the vial sealed and the reaction mixture heated to 90 °C 
for 16 h, unless otherwise stated. The solution was cooled to RT, 
sat. aq. NH4Cl (30 mL) was added and the organic product was 
extracted with EtOAc (3 x 20 mL). The organic washings were 
combined, washed with brine (3 x 20 mL), dried over magnesium 
sulfate, filtered and concentrated in vacuo to give the crude 
product. 
4.1.2.3. Representative Procedure 3: Substitution of N-(3-
chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)sulfonamide 
with aliphatic amines. The requisite sulfonamide (1.0 eq.) was 
stirred with cerium trichloride heptahydrate (0.4 or 1.0 eq., as 
stated) in toluene at RT in a microwave vial for 1.5 h. The 
requisite aniline (3.0 eq.) was added, the vial sealed and the 
reaction mixture heated to 110 °C for 6 h. The solution was 
cooled to RT, sat. aq. NH4Cl (30 mL) was added and the organic 
product was extracted with EtOAc (3 x 20 mL). The organic 
washings were combined, washed with brine (3 x 20 mL), dried 
over magnesium sulfate, filtered and concentrated in vacuo to 
give the crude product. 
4.1.2.4. Representative Procedure 4: Disubstitution of 2,3-
dichloronaphthalene-1,4-dione with phenols. 2,3-
Dichloronaphthalene-1,4-dione (1.0 eq.), the requisite phenol 
(2.2 eq.) and Cs2CO3 (2.2 eq.) were refluxed in THF for 16 h. 
The solution was cooled to RT and partitioned between EtOAc 
(50 mL) and 0.1 M aq. NaOH (30 mL). The organic layer was 
washed with sat. aq. NH4Cl (2 x 20 mL) and brine (3 x 20 mL), 
before being dried over magnesium sulfate, filtered and 
concentrated in vacuo to give the crude product. 
4.1.2.5. Representative Procedure 5: Substitution of 2,3-
diaryloxynaphthalene-1,4-diones with benzenesulfonamide. 
The requisite diphenol (1.0 eq.), benzenesulfonamide (1.0 eq.) 
and Cs2CO3 (1.2 eq.) were refluxed in THF for 1 h, unless 
otherwise stated. The solution was cooled to RT and partitioned 
between EtOAc (50 mL) and 1 M aq. HCl (30 mL). The organic 
layer was washed with brine (3 x 20 mL), before being dried over 
magnesium sulfate, filtered and concentrated in vacuo to give the 
crude product. 
4.1.2.6. Representative Procedure 6: Suzuki coupling of N-(3-
chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-
arylsulfonamide with arylboronic acids. The requisite 
sulfonamide (1.0 eq.), the requisite boronic acid (2.0 eq.), 
O
O
H
N
Y
X
R'
R''
R
1
2
3
4
10
9
7
8
6
5
6'
5'
4'
1'
2'
3'
1''
2' '6' '
5' '
4''
3' '
  
Pd(PPh3)2Cl2 (0.1 eq.) and sat. aq. NaHCO3 were stirred in THF 
in a sealed microwave vial under N2 and heated to 100 °C for 
16 h. The solution was cooled to RT and partitioned between 
EtOAc (50 mL) and sat. aq. NH4Cl (50 mL). The organic layer 
was collected, washed with brine (3 x 20 mL), dried over 
magnesium sulfate, filtered and concentrated in vacuo to give the 
crude product. 
4.1.2.7. Representative Procedure 7: Reduction of 
nitronaphthalene-1,4-diones to aminonapthahlene-1,4-diones. 
The aromatic nitro species (1.0 eq.) and 10% Pd/C catalyst (0.2 
eq.) were stirred in MeOH in a sealed microwave vial under H2 
(1 atm.) at RT for 16 h. The mixture was filtered through Celite® 
to remove the Pd/C catalyst, and the filtrate concentrated in 
vacuo to give the crude product. 
 
4.1.3. N-(3-Phenylamino-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)benzenesulfonamide (3)23 
Following Representative Procedure 2, using 
naphthoquinone 8 (100 mg, 0.29 mmol), aniline (79 µL, 
0.84 mmol) and CeCl3.7H2O (108 mg, 0.29 mmol) in MeOH (5 
mL). Purification via column chromatography on silica gel 
(eluent pet ether:acetone 85:15) gave 3-anilinonaphthoquinone 3 
as a red solid (80 mg, 63%). mp 215-221 °C; HPLC (method A) 
tR 18 min., >99%; δH (400 MHz, DMSO-d6) 6.99-7.09 (3H, m, 
H2’’, H4’’ and H6’’), 7.23 (2H, app. t, J 7.9, H3’’ and H5’’), 7.33-
7.41 (2H, m, H3’ and H5’), 7.45-7.52 (1H, m, H4’), 7.52-7.58 (2H, 
m, H2’ and H6’), 7.73-7.84 (3H, m, H6, H7 and H5 or H8), 7.99-
8.04 (1H, m, H5 or H8), 9.02 (2H, s, aniline-NH and sulfonamide-
NH); m/z (ESI-) 403 ([M-H]-, 100%); λmax (pH 8) 489 nm 
(εN 8700 M-1cm-1), λmax (pH 13.75) 561 nm (εCB 7900 M-1cm-1); 
pKa 9.5. 
 
4.1.4. N-(3-(3’’,5’’-Dimethylphenylamino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (4)21, 23 
Following Representative Procedure 2, using 
naphthoquinone 8 (1.30 g, 3.75 mmol), 3,5-dimethylaniline 
(1.40 mL, 11.25 mmol) and CeCl3.7H2O (1.39 g, 3.75 mmol) in 
MeOH (10 mL). Purification via column chromatography on 
silica gel (eluent pet ether:acetone 90:10 to 50:50) and 
subsequent recrystallisation from toluene gave 3-
anilinonaphthoquinone 4 as a red solid (919 mg, 57%). mp 188-
192 °C (toluene); HPLC (method A) tR 17 min., 97%; δH 
(400 MHz, DMSO-d6) 2.22 (6H, s, 2 x Ar-Me), 6.59 (2H, s, H2’’ 
and H6’’), 6.67 (1H, s, H4’’), 7.34-7.40 (2H, m, H3’ and H5’), 7.47-
7.51 (1H, m, H4’), 7.51-7.56 (2H, m, H2’ and H6’), 7.74-7.83 (3H, 
m, H6, H7 and H5 or H8), 8.00-8.04 (1H, m, H5 or H8), 8.79 (1H, 
s, NH), 9.06 (1H, s, NH); m/z (ESI-) 431 ([M-H]-, 100%); λmax 
(pH 8) 498 nm (εN 11960 M-1cm-1), λmax (pH 13.75) 577 nm 
(εCB 6590 M-1cm-1); pKa 9.2. 
 
4.1.5. N-(3-(4’’-Bromophenylamino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (6)23 
Following Representative Procedure 2, using 
naphthoquinone 8 (300 mg, 0.86 mmol), 4-bromoaniline 
(446 mg, 2.59 mmol) and CeCl3.7H2O (322 mg, 0.86 mmol) in 
MeOH (7 mL). Purification via column chromatography on silica 
gel (eluent pet ether:EtOAc 90:10 to 50:50) gave 3-
anilinonaphthoquinone 6 as a red solid (133 mg, 30%). mp 246-
247 oC; HPLC (method A) tR 17 min., 96%; δH (500 MHz, 
DMSO-d6) 6.98 (2H, d, J 8.4, H2” and H6”), 7.36-7.41 (4H,  m, 
H3’, H5’, H3” and H5”), 7.51 (1H, t, J 7.0, H4’), 7.57 (2H, d, J 7.0, 
H2’ and H6’), 7.75-7.83 (3H, m, H6, H7 and H8), 8.02 (1H, d, J 8.4, 
H5), 9.06 (1H, s, sulfonamide-NH), 9.13 (1H, s, aniline-NH); m/z 
(ESI-) 481 ([M(79Br)-H]-, 83%), 483 ([M(81Br)-H]-, 100%); λmax 
(pH 8) 500 nm (εN 13330 M-1cm-1), λmax (pH 13.75) 570 nm 
(εCB 7790 M-1cm-1); pKa 10.4. 
4.1.6. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)benzenesulfonamide (8)23 
Following Representative Procedure 1, using 2,3-
dichloronaphthalene-1,4-dione 7 (1.00 g, 4.40 mmol), 
benzenesulfonamide (0.69 g, 4.40 mmol) and Cs2CO3 (2.00 g, 
6.16 mmol) in DMF (10 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 75:25) 
gave sulfonamide 8 as a yellow solid (1.39 g, 91%). mp 219-
223 °C; δH (400 MHz, DMSO-d6) 7.56-7.64 (2H, m, H3’ and H5’), 
7.66 (1H, app. t, J 7.1, H4’), 7.81-7.90 (2H, m, H6 and H7), 7.91-
7.98 (H2’, H6’ and H5 or H8), 8.01-8.06 (1H, m, H5 or H8); m/z 
(ESI-) 346 ([M(35Cl)-H]-, 100%). 
 
4.1.7. N-(3-((2’’-Methoxyethyl)amino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (9) 
Following Representative Procedure 3, using 
naphthoquinone 8 (200 mg, 0.58 mmol), 3-methoxyethylamine 
(150 µL, 1.74 mmol) and CeCl3.7H2O (86 mg, 0.23 mmol) in 
toluene (10 mL). Purification via column chromatography (eluent 
pet ether:acetone 70:30) gave 3-aminonaphthoquinone 9 as an 
orange solid (195 mg, 87%). mp 167-169 °C; HPLC (method B) 
tR 7 min., 97%; υmax (KBr) 3312 (N-H), 3235 (N-H), 1676 (C=O), 
1610 (C=O); δH (400 MHz, CDCl3) 3.43 (3H, s, OMe), 3.67 (2H, 
t, J 5.2, 2 x H2’’), 4.16 (2H, q, J 5.2, 2 x H1’’), 6.64 (1H, br. s, 
sulfonamide-NH), 6.72 (1H, br. t, J 5.2, amine-NH), 7.32-7.39 
(2H, m, H3’ and H5’), 7.45-7.52 (1H, m, H4’), 7.55-7.64 (2H, m, 
H6 and H7), 7.66-7.71 (1H, m, H5 or H8), 7.79 (2H, d, J 7.3, H2’ 
and H6’), 8.00-8.06 (1H, m, H5 or H8); δC (100 MHz, CDCl3) 
44.2, 58.8, 70.6, 109.3, 125.9, 126.8, 127.8, 128.6, 130.1, 131.8, 
132.4, 133.1, 134.9, 138.2, 143.9, 178.6, 181.7; m/z (ESI-) 385 
([M-H]-, 100%); HRMS (ESI+) C19H18N2NaO5S+ ([M+Na]+) 
requires 409.0829, found 409.0829; λmax (pH 8) 469 nm 
(εN 1330 M-1cm-1), λmax (pH 13.75) 558 nm (εCB 1010 M-1cm-1); 
pKa 9.8. 
 
4.1.8. N-(3-(Cyclopentylamino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (10) 
Following Representative Procedure 3, using 
naphthoquinone 8 (200 mg, 0.58 mmol), cyclopentylamine 
(172 µL, 1.74 mmol) and CeCl3.7H2O (86 mg, 0.23 mmol) in 
toluene (10 mL). Purification via column chromatography (eluent 
pet ether:acetone 70:30) gave 3-aminonaphthoquinone 10 as a 
red solid (204 mg, 89%). mp 199-201 °C; HPLC (method B) tR 
9 min., 99%; υmax (KBr) 3318 (N-H), 3243 (N-H), 1673 (C=O), 
1612 (C=O); δH (400 MHz, CDCl3) 1.49-1.61 (2H, m, 1 x H2’’ 
and 1 x H5’’), 1.66-1.82 (4H, m, 2 x H3’’ and 2 x H4’’), 2.08-2.21 
(2H, m, 1 x H2’’ and 1 x H5’’), 5.02 (1H, app. sext, J 7.1, H1’’), 
6.41 (1H, d, J 7.1, amine-NH), 6.68 (1H, s, sulfonamide-NH), 
7.32-7.39 (2H, m, H3’ and H5’), 7.45-7.52 (1H, m, H4’), 7.55-7.64 
(2H, m, H6 and H7), 7.66-7.72 (1H, m, H5 or H8), 7.80 (2H, d, J 
7.8, H2’ and H6’), 7.99-8.06 (1H, m, H5 or H8); δC (100 MHz, 
CDCl3) 24.1, 34.5, 55.0, 109.1, 125.9, 126.7, 127.8, 128.6, 130.1, 
131.9, 132.3, 133.1, 134.9, 138.3, 143.5, 178.5, 182.0; m/z (ESI-) 
395 ([M-H]-, 100%); HRMS (ESI+) C21H20N2NaO4S+ ([M+Na]+) 
requires 419.1036, found 419.1036; λmax (pH 8) 471 nm 
(εN 10080 M-1cm-1) λmax (pH 13.75) 553 nm (εCB 4470 M-1cm-1); 
pKa 10.1. 
 
4.1.9. N-(3-(Benzylamino)-1,4-dioxo-1,4-dihydronaphthalen-
2-yl)benzenesulfonamide (11) 
Following Representative Procedure 3, using 
naphthoquinone 8 (100 mg, 0.29 mmol), benzylamine (100 µL, 
0.86 mmol) and CeCl3.7H2O (107 mg, 0.29 mmol) in toluene (4 
mL). Purification via column chromatography (eluent pet 
ether:acetone 85:15) and subsequent recrystallisation from 
toluene gave 3-aminonaphthoquinone 11 as an orange solid 
  
(50 mg, 42%). mp 206-211 oC (toluene); HPLC (method A) tR 
16 min., 99%; υmax (neat) 3342 (N-H), 1675 (C=O), 1612 (C=O); 
δH (500 MHz, CDCl3) 5.12 (2H, d, J 5.8, benzyl-CH2), 6.56 (1H, 
s, sulfonamide-NH), 6.59 (1H, br. s, amine-NH), 7.30-7.35 (1H, 
m, H4”), 7.35-7.40 (6H, m, H3’, H5’, H2”, H3’’, H5” and H6”), 7.50 
(1H, t, J 7.7, H4’), 7.57-7.64 (2H, m, H6 and H7), 7.67-7.71 (1H, 
m, H8), 7.82 (2H, d, J 7.6, H2’ and H6’), 8.02-8.05 (1H, m, H5); δC 
(125 MHz, CDCl3) 48.9, 109.8, 126.0, 126.8, 127.8, 127.9, 
128.1, 128.7, 128.9, 130.0, 131.3, 132.5, 133.1, 134.9, 137.8, 
138.3, 143.6, 178.8, 181.8; m/z (ESI-) 417 ([M-H]-, 100%); 
HRMS (ESI+) C23H18N2NaO4S+ ([M+Na]+) requires 441.0879, 
found 441.0865; λmax (pH 8) 486 nm (εN 10480 M-1cm-1), λmax 
(pH 13.75) 560 nm (εCB 5770 M-1cm-1); pKa 10.4. 
 
4.1.10. N-(3-Phenoxy-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)benzenesulfonamide (17) 
Following Representative Procedure 4, using 2,3-
dichloronaphthalene-1,4-dione 7 (454 mg, 2.00 mmol), phenol 
(414 mg, 4.40 mmol) and Cs2CO3 (1434 mg, 4.40 mmol) in THF 
(30 mL) gave intermediate diphenoxy 14 as an orange solid 
(430 mg, 63%). mp 188-193 °C; υmax (neat) 1662 (C=O), 1591 
(C=O); δH (400 MHz, CDCl3) 6.88-6.94 (4H, m, H2’, H6’, H2’’ and 
H6’’), 7.02-7.09 (2H, m, H4’ and H4’’), 7.21-7.28 (4H, m, H3’, H5’, 
H3’’ and H5’’), 7.75-7.81 (2H, m, H6 and H7), 8.10-8.16 (2H, m, 
H5 and H8); δC (100 MHz, CDCl3) 116.6, 123.6, 126.8, 129.4, 
130.8, 134.3, 146.1, 156.5, 180.4; m/z (ESI+) 343 ([M+H]+, 
80%), 365 ([M+Na]+, 100%); HRMS (ESI+) C22H14NaO4+ 
([M+Na]+) requires 365.0784, found 365.0768. Then, following 
Representative Procedure 5, using naphthoquinone 14 without 
further purification (400 mg, 1.17 mmol), benzenesulfonamide 
(184 mg, 1.17 mmol) and Cs2CO3 (458 mg, 1.40 mmol) in THF 
(30 mL) for 16 h and subsequent recrystallisation from toluene 
gave 2-sulfonamidonaphthoquinone 17 as a yellow solid (175 
mg, 67%). mp 216-219 °C (toluene); HPLC (method A) tR 18 
min., 95%; υmax (neat) 3235 (N-H), 1668 (C=O), 1655 (C=O); δH 
(500 MHz, DMSO-d6) 6.82-6.86 (2H, m, H2’’ and H6’’), 6.99-7.04 
(1H, m, H4’’), 7.18-7.24 (2H, m, H3’’ and H5’’), 7.46-7.51 (2H, m, 
H3’ and H5’), 7.53-7.57 (1H, m, H4’), 7.81-7.92 (5H, m, H5, H6, 
H7, H2’ and H6’), 8.03-8.06 (1H, m, H8), 10.30 (1H, br. s, NH); δC 
(125 MHz, DMSO-d6) 116.4, 122.7, 126.1, 126.1, 126.3, 128.7, 
129.1, 130.6, 130.6, 132.3, 132.4, 134.4, 134.5, 141.7, 145.1, 
156.4, 179.1, 180.6; m/z (ESI-) 405 ([M-H]-, 100%); HRMS 
(ESI+) C22H15NNaO5S+ ([M+Na]+) requires 428.0563, found 
428.0565; λmax (pH 8) < 400 nm, λmax (pH 13.75) 473 nm 
(εCB 7080 M-1cm-1); pKa 5.0. 
 
4.1.11. N-(3-(3’’,5’’-Dimethylphenoxy)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (18) 
Following Representative Procedure 4, using 2,3-
dichloronaphthalene-1,4-dione 7  (454 mg, 2.00 mmol), 3,5-
dimethylphenol (537 mg, 4.40 mmol) and Cs2CO3 (1434 mg, 
4.40 mmol) in THF (30 mL) gave intermediate diaryloxy 15 as 
an orange solid (709 mg, 89%). mp 175-177 °C; υmax (neat) 1665 
(C=O), 1590 (C=O); δH (500 MHz, CDCl3) 2.18 (12H, s, 4 x Ar-
Me), 6.65 (2H, s, H4’ and H4’’), 6.73 (4H, s, H2’, H6’, H2’’ and 
H6’’), 7.88-7.93 (2H, m, H6 and H7), 8.01-8.06 (2H, m, H5 and 
H8); δC (125 MHz, CDCl3) 20.7, 113.6, 124.3, 126.0, 131.0, 
134.3, 138.8, 146.2, 156.7, 180.2; m/z (ESI+) 399 ([M+H]+, 
100%), 421 ([M+Na]+, 20%); HRMS (ESI+) C26H22NaO4+ 
([M+Na]+) requires 421.1410, found 421.1391. Then, following 
Representative Procedure 5, using naphthoquinone 15 without 
further purification (400 mg, 1.01 mmol), benzenesulfonamide 
(158 mg, 1.01 mmol) and Cs2CO3 (393 mg, 1.21 mmol) in THF 
(30 mL) and subsequent recrystallisation from toluene gave 2-
sulfonamidonaphthoquinone 18 as an orange-brown solid 
(248 mg, 57%). mp 218-223 °C (toluene); HPLC (method A) 
tR 18 min., 96%; υmax (neat) 3242 (N-H), 1662 (C=O), 1641 
(C=O); δH (500 MHz, CDCl3) 2.22 (6H, s, 2 x Ar-Me), 6.28 (2H, 
s, H2’’ and H6’’), 6.66 (1H, s, H4’’), 7.32-7.37 (2H, m, H3’ and H5’), 
7.43-7.49 (1H, m, H4’), 7.72-7.77 (3H, m, H6, H7 and NH), 7.80-
7.85 (2H, m, H2’ and H6’), 7.94-7.99 (1H, m, H5), 8.12-8.18 (1H, 
m, H8); δC (125 MHz, CDCl3) 21.2, 114.5, 125.3, 126.8, 126.9, 
127.1, 128.5, 129.8, 131.1, 131.1, 132.7, 133.9, 134.9, 138.8, 
140.1, 141.2, 156.0, 178.8, 180.5; m/z (ESI+) 434 ([M+H]+, 
100%), 456 ([M+Na]+, 60%); HRMS (ESI+) C24H19NNaO5S+ 
([M+Na]+) requires 456.0876, found 456.0857; λmax (pH 8) < 400 
nm, λmax (pH 13.75) 474 nm (εCB 7200 M-1cm-1); pKa 5.0. 
 
4.1.12. N-(3-(4’’-Bromophenoxy)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (19) 
Following Representative Procedure 4, using 2,3-
dichloronaphthalene-1,4-dione 7 (454 mg, 2.00 mmol), 4-
bromophenol (761 mg, 4.40 mmol) and Cs2CO3 (1434 mg, 
4.40 mmol) in THF (30 mL) gave intermediate diaryloxy 16 as a 
yellow solid (715 mg, 72%). mp 182-185 °C; υmax (neat) 1677 
(C=O), 1659 (C=O); δH (500 MHz, CDCl3) 6.78-6.82 (4H, m, 
H2’, H6’, H2’’ and H6’’), 7.34-7.39 (4H, m, H3’, H5’, H3’’ and H5’’), 
7.78-7.82 (2H, m, H6 and H7), 8.10-8.15 (2H, m, H5 and H8); δC 
(125 MHz, CDCl3) 116.4, 118.3, 126.9, 130.6, 132.4, 134.5, 
145.7, 155.4, 180.0; m/z (FI) 498 ([M(79Br79Br)]+, 50%), 500 
([M(79Br)(81Br)]+, 100%), 502 ([M(81Br)(81Br)]+, 50%); HRMS 
(FI) C22H12O4Br2 ([M(79Br79Br)]+) requires 497.9092, found 
497.9102. Then, following Representative Procedure 5, using 
naphthoquinone 16 without further purification (400 mg, 
0.80 mmol), benzenesulfonamide (126 mg, 0.80 mmol) 
and Cs2CO3 (313 mg, 0.96 mmol) in THF (30 mL) and 
subsequent recrystallisation from toluene gave 2-
sulfonamidonaphthoquinone 19 as a yellow solid (210 mg, 43%). 
mp 215-218 °C (toluene); HPLC (method A) tR 19 min., 97%; 
υmax (neat) 3251 (N-H), 1675 (C=O), 1649 (C=O); δH (500 MHz, 
CDCl3) 6.57-6.62 (2H, m, H2’’ and H6’’), 7.29-7.34 (2H, m, H3’’ 
and H5’’), 7.36-7.42 (2H, m, H3’ and H5’), 7.48-7.53 (1H, m, H4’), 
7.72-7.84 (5H, m, H6, H7, H2’, H6’ and NH), 7.93-7.98 (1H, m, 
H5), 8.13-8.18 (1H, m, H8); δC (125 MHz, CDCl3) 116.1, 118.7, 
126.9, 126.9, 127.0, 128.8, 129.7, 130.9, 131.0, 132.1, 133.0, 
134.1, 135.1, 140.2, 140.4, 155.0, 178.5, 180.3; m/z (ESI-) 482 
([M(79Br)-H]-, 100%), 484 ([M(81Br)-H]-, 100%); HRMS (ESI+) 
C22H14BrNNaO5S+ ([M(81Br)+Na]+) requires 507.9649, found 
507.9666; λmax (pH 8) < 400 nm, λmax (pH 13.75) 473 nm (εCB 
8550 M-1cm-1); pKa 5.0. 
 
4.1.13. N-(3-(2’’-Chlorophenyl)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (20) 
Following Representative Procedure 6, using 
naphthoquinone 8 (200 mg, 0.58 mmol), 2-chlorophenylboronic 
acid (181 mg, 1.14 mmol), Pd(PPh3)2Cl2 (41 mg, 0.06 mmol) and 
sat. aq. NaHCO3 (5 mL) in THF (22 mL). Purification via 
column chromatography on silica gel (eluent pet ether:acetone 
75:25) and subsequent recrystallisation from toluene gave 3-
arylnaphthoquinone 20 as a yellow solid (119 mg, 48%). 
mp 194-196 °C (toluene); HPLC (method B) tR 10 min., 96%; 
υmax (KBr) 3206 (N-H), 1673 (C=O), 1656 (C=O); δH (400 MHz, 
Acetone-d6) 7.21-7.36 (4H, m, H3’’, H4’’, H5’’ and H6’’) 7.44-7.53 
(2H, m, H3’ and H5’), 7.59 (1H, s, H4’), 7.67-7.76 (2H, m, H2’ and 
H6’), 7.85-7.97 (2H, m, H6 and H7), 8.05-8.14 (2H, m, H5 and 
H8), 8.61 (1H, br. s, NH); δC (100 MHz, Acetone-d6) 126.7, 
126.8, 126.8, 126.9, 129.1, 129.4, 130.8, 131.2, 131.6, 132.4, 
132.6, 132.9, 134.3, 134.4, 134.8, 135.2, 140.7, 141.8, 181.2, 
182.5; m/z (ESI-) 422 ([M-H]-, 100%); HRMS (ESI+) 
C22H14ClNNaO4S+ ([M+Na]+) requires 446.0224, found 
446.0225; λmax (pH 8) < 400 nm, λmax (pH 13.75) 474 nm (εCB 
8860 M-1cm-1); pKa 4.9. 
  
4.1.14. N-(3-(3’’-Chlorophenyl)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (21) 
Following Representative Procedure 6, using 
naphthoquinone 8 (200 mg, 0.58 mmol), 3-chlorophenylboronic 
acid (181 mg, 1.14 mmol), Pd(PPh3)2Cl2 (41 mg, 0.06 mmol) and 
sat. aq. NaHCO3 (5 mL) in THF (22 mL). Purification via 
column chromatography on silica gel (eluent pet ether:acetone 
75:25) and subsequent recrystallisation from toluene gave 3-
arylnaphthoquinone 21 as a yellow solid (87 mg, 35%). mp 
168-172 °C (toluene); HPLC (method B) tR 11 min., 99%; υmax 
(KBr) 3229 (N-H), 1670 (C=O), 1651 (C=O); δH (400 MHz, 
Acetone-d6) 7.26-7.31 (3H, m, H4’’, H5’’ and H6’’), 7.33 (1H, s, 
H2’’), 7.44-7.51 (2H, m, H3’ and H5’), 7.57-7.63 (1H, m, H4’), 
7.63-7.69 (2H, m, H2’ and H6’), 7.84-7.94 (2H, m, H6 and H7), 
8.04-8.13 (2H, m, H5 and H8), 8.53 (1H, br. s, NH); δC (100 
MHz, Acetone-d6) 126.6, 126.7, 126.9, 128.9, 129.1, 129.6, 
129.7, 130.9, 131.2, 132.5, 133.1, 133.3, 134.3, 134.4, 135.1, 
136.1, 139.7, 141.7, 181.6, 183.4; m/z (ESI-) 422 ([M-H]-, 
100%); HRMS (ESI-) C22H13ClNO4S- ([M-H]-) requires 
422.0259, found 422.0258; λmax (pH 8) < 400 nm, λmax (pH 
13.75) 473 nm (εCB  3890 M-1cm-1); pKa 4.5. 
 
4.1.15. N-(3-(4’’-Chlorophenyl)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (22) 
Following Representative Procedure 6, using 
naphthoquinone 8 (200 mg, 0.58 mmol), 4-chlorophenylboronic 
acid (181 mg, 1.14 mmol), Pd(PPh3)2Cl2 (41 mg, 0.06 mmol) and 
sat. aq. NaHCO3 (5 mL) in THF (22 mL). Purification via 
column chromatography on silica gel (eluent pet ether:acetone 
80:20) and subsequent recrystallisation from toluene gave 3-
arylnaphthoquinone 22 as a yellow solid (115 mg, 47%). mp 222-
223 °C (toluene); HPLC (method B) tR 11 min., 95%; υmax (KBr) 
3240 (N-H), 1627 (C=O), 1655 (C=O); δH (400 MHz, DMSO-d6) 
7.21-7.27 (2H, m, H2’’ and H6’’ or H3’’ and H5’’), 7.30-7.38 (2H, 
m, H2’’ and H6’’ or H3’’ and H5’’), 7.43-7.51 (2H, m, H3’ and H5’), 
7.54-7.66 (3H, m, H2’, H4’ and H6’), 7.80-7.93 (2H, m, H6 and 
H7), 7.97-8.05 (2H, m, H5 and H8), 9.93 (1H, br. s, NH); δC (100 
MHz, DMSO-d6) 126.4, 126.7, 127.0, 127.2, 128.4, 129.5, 129.8, 
131.2, 131.5, 132.4, 133.1, 134.2, 135.1, 135.5, 140.0, 142.7, 
182.0, 184.0; m/z (ESI-) 422 ([M-H]-, 100%); HRMS (ESI-) 
C22H13ClNO4S- ([M-H]-) requires 422.0259, found 422.0260; λmax 
(pH 8) < 400 nm, λmax (pH 13.75) 477 nm (εCB 6810 M-1cm-1); 
pKa 5.0. 
 
4.1.16. N-(3-(3’’-Formylphenyl)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (23) 
Following Representative Procedure 6, using 
naphthoquinone 8 (200 mg, 0.58 mmol), 3-formylphenylboronic 
acid (174 mg, 1.14 mmol), Pd(PPh3)2Cl2 (41 mg, 0.06 mmol) and 
sat. aq. NaHCO3 (5 mL) in THF (22 mL). Purification via 
column chromatography on silica gel (eluent pet ether:acetone 
90:10 to 70:30) and subsequent recrystallisation from toluene 
gave 3-arylnaphthoquinone 23 as a yellow solid (74 mg, 31%). 
mp 200-201 °C (toluene); HPLC (method B) tR 9 min., >99%; 
υmax (KBr) 3229 (N-H), 1698 (C=O), 1671 (C=O), 1651 (C=O); 
δH (400 MHz, Acetone-d6) 7.37-7.45 (2H, m, two of H2’’, H4’’, 
H5’’ and H6’’), 7.49-7.55 (4H, m, H3’, H5’ and two of H2’’, H4’’, H5’’ 
and H6’’), 7.63-7.70 (1H, m, H4’), 7.75-7.85 (2H, m, H2’ and H6’), 
7.87-7.97 (2H, m, H6 and H7), 8.06-8.16 (2H, m, H5 and H8), 8.69 
(1H, br. s, NH), 9.89 (1H, s, CHO); δC (100 MHz, Acetone-d6) 
126.5, 126.7, 126.9, 128.7, 129.2, 129.8, 131.2, 132.1, 132.5, 
133.0, 133.4, 134.4, 135.2, 136.2, 136.5, 137.2, 139.6, 141.7, 
181.7, 183.6, 192.0; m/z (ESI-) 416 ([M-H]-, 100%); HRMS 
(ESI-) C23H14NO5S- ([M-H]-) requires 416.0598, found 416.0596; 
λmax (pH 8) < 400 nm, λmax (pH 13.75) 474 nm (εCB 
5720 M-1cm-1); pKa 5.0. 
4.1.17. N-(3-(4’’-Formylphenyl)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (24) 
Following Representative Procedure 6, using 
naphthoquinone 8 (200 mg, 0.58 mmol), 4-
formylbenzeneboronic acid (174 mg, 1.14 mmol), Pd(PPh3)2Cl2 
(41 mg, 0.06 mmol) and sat. aq. NaHCO3 (5 mL) in THF 
(22 mL). Purification via column chromatography on silica gel 
(eluent pet ether:acetone 90:10 to 70:30) and subsequent 
recrystallization from toluene gave 3-arylnaphthoquinone 24 as a 
yellow solid (59 mg, 24%). mp 200-202 °C (toluene); HPLC 
(method B) tR 9 min., 99%; υmax (KBr) 3234 (N-H), 1698 (C=O), 
1668 (C=O), 1650 (C=O); δH (400 MHz, DMSO-d6) 7.40-7.47 
(4H, m, H3’, H5’ and H2’’ and H6’’ or H3’’ and H5’’), 7.52-7.58 (1H, 
m, H4’), 7.58-7.63 (2H, m, H2’ and H6’), 7.76-7.84 (2H, m, H2’’ 
and H6’’ or H3’’ and H5’’), 7.85-7.96 (2H, m, H6 and H7), 7.98-8.08 
(2H, m, H5 and H8), 10.02 (2H, s, CHO and NH); δC (100 MHz, 
DMSO-d6) 126.7, 127.0, 127.2, 129.3, 129.5, 131.5, 132.1, 
132.4, 133.1, 135.1, 135.6, 136.5, 138.7, 139.1, 140.0, 142.5, 
182.0, 183.9, 193.8; m/z (ESI-) 416 ([M-H]-, 100%); HRMS   
(ESI-) C23H14NO5S- ([M-H]-) requires 416.0598, found 416.0600; 
λmax (pH 8) < 400 nm, λmax (pH 13.75) 477 nm (εCB           
5880 M-1cm-1); pKa 4.6. 
 
4.1.18. N-(3-(Furan-2’’-yl)-1,4-dioxo-1,4-dihydronaphthalen-
2-yl)benzenesulfonamide (25) 
Following Representative Procedure 6, using 
naphthoquinone 8 (200 mg, 0.58 mmol), furan-2-ylboronic acid 
(130 mg, 1.14 mmol), Pd(PPh3)2Cl2 (41 mg, 0.06 mmol) and sat. 
aq. NaHCO3 (5 mL) in THF (22 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 90:10 to 
70:30) and subsequent recrystallisation from toluene gave 3-
arylnaphthoquinone 25 as a purple solid (100 mg, 45%). mp 144-
146 °C (toluene); HPLC (method B) tR 10 min., 99%; υmax (KBr) 
3242 (N-H), 1668 (C=O), 1648 (C=O); δH (400 MHz, Acetone-
d6) 6.66-6.70 (1H, dd, J 3.5, 1.7, H4’’), 7.45 (1H, d, J 3.5, H5’’), 
7.53-7.62 (2H, m, H3’ and H5’), 7.62-7.68 (1H, m, H4’), 7.72 (1H, 
d, J 1.7, H3’’), 7.81-7.92 (2H, m, H6 and H7) 7.93-8.01 (3H, m, 
H2’, H6’ and H5 or H8), 8.09-8.14 (1H, m, H5 or H8), 8.98 (1H, s, 
NH); δC (100 MHz, Acetone-d6) 114.0, 120.6, 125.5, 127.5, 
127.9, 128.4, 130.2, 132.4, 133.6, 134.1, 135.5, 135.9, 137.4, 
143.5, 146.2, 147.4, 181.9, 183.8; m/z (ESI-) 378 ([M-H]-, 
100%); HRMS (ESI+) C20H13NNaO5S+ ([M+Na]+) requires 
402.0407, found 402.0407; λmax (pH 8) 458 nm (εN 
11320 M-1cm-1), λmax (pH 13.75) 502 nm (εCB 7180 M-1cm-1); pKa 
5.1. 
  
4.1.19. N-(3-(Furan-3’’-yl)-1,4-dioxo-1,4-dihydronaphthalen-
2-yl)benzenesulfonamide (26) 
Following Representative Procedure 6, using 
naphthoquinone 8 (200 mg, 0.58 mmol), furan-3-ylboronic acid 
(130 mg, 1.14 mmol), Pd(PPh3)2Cl2 (41 mg, 0.06 mmol) and sat. 
aq. NaHCO3 (5 mL) in THF (22 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 75:25) and 
subsequent recrystallisation from toluene gave 3-
arylnaphthoquinone 26 as a yellow solid (51 mg, 23%). mp 211-
214 °C (toluene); HPLC (method B) tR 9 min., 99%; υmax (KBr) 
3231 (N-H), 1664 (C=O), 1651 (C=O); δH (400 MHz, DMSO-d6) 
6.95 (1H, app. s, H5’’), 7.46-7.57 (2H, m, H3’ and H5’), 7.58-7.66 
(1H, m, H4’), 7.73-7.75 (1H, m, H4’’), 7.76 -7.80 (2H, m, H2’ and 
H6’), 7.82-7.93 (3H, m, H6, H7 and H5 or H8), 7.99-8.09 (1H, m, 
H5 or H8), 8.18 (1H, app. s, H2’’), 10.04 (1H, br. s, NH); δC 
(100 MHz, DMSO-d6) 112.5, 116.8, 126.8, 127.2, 127.3, 129.6, 
131.3, 132.6, 133.3, 134.5, 135.1, 135.3, 137.8, 142.7, 143.5, 
146.8, 181.5, 184.3; m/z (ESI-) 378 ([M-H]-, 100%); HRMS 
(ESI+) C20H13NNaO5S+ ([M+Na]+) requires 402.0407, found 
  
402.0403; λmax (pH 8) 444 nm (εN 15220 M-1cm-1), λmax 
(pH 13.75) 509 nm (εCB 7840 M-1cm-1); pKa 5.0. 
 
4.1.20. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)methanesulfonamide (31) 
Following Representative Procedure 1, using 2,3-
dichloronaphthalene-1,4-dione 7 (500 mg, 2.20 mmol), 
methanesulfonamide (209 mg, 2.20 mmol) and Cs2CO3 (287 mg, 
0.88 mmol) in DMF (5 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 90:10) 
gave sulfonamide 31 as a yellow solid (246 mg, 39%). mp 195-
200 °C; υmax (neat) 3241 (N-H), 1680 (C=O), 1659 (C=O); δH 
(500 MHz, DMSO-d6) 3.44 (3H, s, Me), 7.89-7.94 (2H, m, H6 
and H7), 8.04-8.10 (2H, m, H5 and H8), 10.10 (1H, br. s, NH); δC 
(125 MHz, DMSO-d6) 43.3, 126.6, 126.8, 130.7, 130.9, 133.7, 
134.5, 134.7, 141.0, 177.5, 179.3; m/z (ESI-) 284 ([M(35Cl)-H]-, 
100%); HRMS (ESI+) C11H9ClNNaO4S+ ([M(35Cl)+Na]+) 
requires 307.9755, found 307.9755. 
 
4.1.21. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-
cyclohexanesulfonamide (32) 
Following Representative Procedure 1, using 2,3-
dichloronaphthalene-1,4-dione 7 (400 mg, 1.76 mmol), 
cyclohexanesulfonamide 29 (287 mg, 1.76 mmol) and Cs2CO3 
(804 mg, 2.46 mmol) in DMF (5 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 90:10 to 
75:25 and then pet ether:EtOAc 80:20 to 50:50) gave 
sulfonamide 32 as a yellow solid (396 mg, 64%). mp 178-179 
°C; υmax (neat) 3254 (N-H), 1679 (C=O), 1595 (C=O); δH (500 
MHz, CDCl3) 1.24-1.34 (1H, m, H4’), 1.44 (2H, m, H3’ and H5’), 
1.71 (2H, m, H2’ and H6’), 1.76-1.82 (1H, m, H4’), 1.99 (2H, m, 
H3’ and H5’), 2.37 (2H, app. d, J 12.6, H2’ and H6’), 4.14 (1H, m, 
H1’), 6.93 (1H, s, NH), 7.76-7.82 (2H, m, H6 and H7), 8.12-8.19 
(2H, m, H5 and H8); δC (125 MHz, CDCl3) 25.0, 25.0, 26.4, 64.0, 
127.3, 127.4, 128.8, 130.4, 131.0, 134.2, 134.8, 141.1, 177.0, 
178.6; m/z (ESI-) 352 ([M(35Cl)-H]-, 100%), 354 ([M(37Cl)-H]-, 
33%); HRMS (ESI+) C16H16ClNNaO4S ([M(35Cl)+Na]+) requires 
376.0381, found 376.0366. 
 
4.1.22. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-
2’-methylbenzenesulfonamide (33) 
Following Representative Procedure 1, using 2,3-
dichloronaphthalene-1,4-dione 7 (500 mg, 2.20 mmol), ortho-
toluenesulfonamide (377 mg, 2.20 mmol) and Cs2CO3 (1000 mg, 
3.08 mmol) in DMF (5 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 80:20) 
gave sulfonamide 33 as a yellow solid (555 mg, 70%). mp 157-
162 °C; υmax (neat) 3370 (N-H), 1666 (C=O), 1589 (C=O); δH 
(500 MHz, DMSO-d6) 2.65 (3H, s, Me), 7.39 (1H, app. t, J 7.4, 
H5’), 7.44 (1H, d, J 7.4, H3’), 7.56 (1H, app. td, J 7.4, 1.3, H4’), 
7.84-7.93 (3H, m, H6, H7 and H6’), 7.95-7.98 (1H, m, H5 or H8), 
8.04-8.08 (1H, m, H5 or H8); δC (125 MHz, DMSO-d6) 20.0, 
125.9, 126.6, 126.7, 128.3, 130.4, 131.0, 132.2, 132.6, 134.5, 
134.7, 136.2, 140.5, 141.1, 177.4, 178.8; m/z (ESI+) 384 
([M(35Cl)+Na]+, 100%); HRMS (ESI+) C17H13ClNNaO4S+ 
([M(35Cl)+Na]+) requires 384.0068, found 384.0057. 
 
4.1.23. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-
2’-nitrobenzenesulfonamide (34) 
Following Representative Procedure 1, using 2,3-
dichloronaphthalene-1,4-dione 7 (500 mg, 2.20 mmol), 2-
nitrobenzenesulfonamide (445 mg, 2.20 mmol) and Cs2CO3 
(287 mg, 0.88 mmol) in DMF (5 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 75:25) 
gave sulfonamide 34 as a yellow solid (378 mg, 44%). 
mp > 280 °C; υmax (neat) 3396 (N-H), 1677 (br., C=O); δH (500 
MHz, DMSO-d6) 7.65-7.82 (5H, m, H6, H7, H4’, H5’ and H6’), 
7.86 (1H, dd, J 7.9, 1.0, H5 or H8), 7.97 (1H, dd, J 7.6, 1.0, H5 or 
H8), 8.13 (1H, dd, J 7.9, 1.3, H3’); δC (125 MHz, DMSO-d6) 
123.4, 125.7, 126.4, 128.7, 130.8, 131.5, 131.6, 131.9, 132.9, 
134.1, 138.7, 146.8, 149.1, 176.7, 179.6; m/z (ESI-) 391 
([M(35Cl)-H]-, 100%); HRMS (ESI-) C16H8ClN2O6S- ([M(35Cl)-
H]-) requires 390.9797, found 390.9797. 
 
4.1.24. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-
2’,6’-difluorobenzenesulfonamide (35) 
Following Representative Procedure 1, using 2,3-
dichloronaphthalene-1,4-dione 7 (500 mg, 2.20 mmol), 2,6-
difluorobenzenesulfonamide (425 mg, 2.20 mmol) and Cs2CO3 
(1000 mg, 3.08 mmol) in DMF (5 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 70:30) 
gave sulfonamide 35 as a yellow solid (620 mg, 67%). mp 261-
267 °C; υmax (neat) 3444 (N-H), 1657 (C=O), 1611 (C=O); δH 
(400 MHz, DMSO-d6) 7.32-7.40 (2H, m, H3’ and H5’), 7.74-7.84  
(1H, m, H4’), 7.87-7.97 (2H, m, H6 and H7), 7.98-8.03 (1H, m, H5 
or H8), 8.09-8.14 (1H, m, H5 or H8); δF (470 MHz, DMSO-d6) 
-108.8;
 
δC (100 MHz, DMSO-d6) 113.1 (dd, J 19.8, 3.0), 120.6 
(m), 126.7, 126.8, 130.3, 130.9, 134.5, 134.7, 135.0 (m), 135.4, 
140.8, 158.3 (dd, J 256.1, 3.8), 177.4, 179.0; m/z (ESI-) 382 
([M(35Cl)-H]-, 100%), 384 ([M(37Cl)-H]-, 50%); HRMS (ESI-) 
C16H7ClF2NO4S- ([M(35Cl)-H]-) requires 381.9758, found 
381.9765. 
 
4.1.25. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-
3’-nitrobenzenesulfonamide (36) 
Following Representative Procedure 1, using 2,3-
dichloronaphthalene-1,4-dione 7 (500 mg, 2.20 mmol), 3-
nitrobenzenesulfonamide (445 mg, 2.20 mmol) and Cs2CO3 
(1004 mg, 3.08 mmol) in DMF (5 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 80:20 to 
50:50) gave sulfonamide 36 as a yellow solid (837 mg, quant.). 
mp 258-263 °C; υmax (neat) 3430 (N-H), 1678 (C=O), 1588 
(C=O); δH (500 MHz, DMSO-d6) 7.71 (1H, app. td, J 7.6, 1.3, H6 
or H7), 7.76-7.82 (2H, m, H6 or H7 and H5’), 7.88 (1H, dd, J 7.6, 
1.3, H5 or H8), 7.96 (1H, dd, J 7.6, 1.3, H5 or H8), 8.28 (1H, ddd, 
J 8.1, 2.0, 0.9, H4’ or H6’), 8.32 (1H, ddd, J 8.1, 2.0, 0.9, H4’ or 
H6’), 8.66 (1H, t, J 2.0, H2’); δC (125 MHz, DMSO-d6) 120.1, 
124.5, 124.5, 125.5, 126.3, 130.1, 130.8, 131.7, 132.1, 132.5, 
134.0, 147.3, 149.7, 151.0, 176.3, 179.8; m/z (ESI-) 391 
([M(35Cl)-H]-, 100%), 393 ([M(37Cl)-H]-, 33%); HRMS (ESI-) 
C16H8ClN2O6S- ([M(35Cl)-H]-) requires 390.9797, found 
390.9801. 
 
4.1.26. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-
4’-methylbenzenesulfonamide (37) 
2,3-dichloronaphthalene-1,4-dione 7 (5.00 g, 22.00 mmol), 
para-toluenesulfonamide (4.90 g, 28.60 mmol) and Cs2CO3 
(9.30 g, 28.60 mmol) were stirred at reflux in anhydrous toluene 
(100 mL) for 18 h under argon. The reaction mixture was 
concentrated in vacuo and re-suspended in water (40 mL). The 
suspension was filtered and washed with hot water (2 x 10 mL). 
The precipitate was dried under vacuum to give sulfonamide 37 
as a red powder (12.10 g, 14.50 mmol, 66%). mp 292-293 oC; 
υmax (neat) 1681 (C=O), 1625 (C=O); δH (400 MHz, DMSO-d6) 
2.34 (3H, s, Me), 7.21-7.26 (2H, m, H3’ and H5’), 7.64-7.70 (1H, 
m, H6 or H7), 7.72-7.77 (3H, m, H2’, H6’ and H6 or H7), 7.83-7.87 
(1H, m, H5 or H8), 7.90-7.94 (1H, m, H5 or H8); δC (100 MHz, 
DMSO-d6) 21.7, 126.0, 126.3, 127.0, 129.2, 132.0, 132.7, 133.4, 
134.6, 140.0, 146.6, 153.4, 176.4, 180.9; m/z (ESI-) 360 
([M(35Cl)-H]-, 100%), 362 ([M(37Cl)-H]-, 40%); HRMS (ESI+) 
C17H12ClNO4SNa+ ([M(35Cl)+Na]+) requires 384.0068, found 
384.0061. 
  
4.1.27. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-
4’-fluorobenzenesulfonamide (38) 
Following Representative Procedure 1, using 2,3-
dichloronaphthalene-1,4-dione 7 (500 mg, 2.20 mmol), 4-
fluorobenzenesulfonamide (386 mg, 2.20 mmol) and Cs2CO3 
(1000 mg, 3.08 mmol) in DMF (5 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 75:25) 
gave sulfonamide 38 as a yellow solid (515 mg, 63%). 
mp > 280 °C; υmax (neat) 1676 (C=O), 1591 (C=O); δH 
(500 MHz, DMSO-d6) 7.31 (2H, app. t, J 9.0, H3’ and H5’), 7.73 
(1H, app. td, J 7.6, 1.4, H6 or H7), 7.79 (1H, app. td, J 7.6, 1.4, H6 
or H7), 7.89 (1H, dd, J 7.6, 1.4, H5 or H8), 7.92-7.97 (3H, m, H2’, 
H6’ and H5 or H8); δF (470 MHz, DMSO-d6) -110.4; δC (125 MHz, 
DMSO-d6) 115.1 (d, J 21.9), 125.6, 126.3, 128.3 (d, J 8.6), 128.3, 
130.9, 132.1, 132.6, 132.6, 134.0, 143.5, 162.9 (d, J 248.0), 
176.1, 179.7; m/z (ESI-) 364 ([M(35Cl)-H]-, 100%), 366 
([M(37Cl)-H]-, 55%); HRMS (ESI-) C16H8ClFNO4S- 
([M(35Cl)-H]-) requires 363.9852, found 363.9853. 
 
4.1.28. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)furan-2’-sulfonamide (39) 
Following Representative Procedure 1, using 2,3-
dichloronaphthalene-1,4-dione 7 (500 mg, 2.20 mmol), furan-2-
sulfonamide 30 (324 mg, 2.20 mmol) and Cs2CO3 (1004 mg, 
3.08 mmol) in DMF (5 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 90:10 to 
50:50) gave sulfonamide 39 as a yellow solid (634 mg, 85%). 
mp 258-259 °C; υmax (neat) 3388 (N-H), 1668 (C=O), 1652 
(C=O); δH (500 MHz, DMSO-d6) 6.57 (1H, dd, J 3.1, 1.7, H4’), 
6.91 (1H, d, J 3.1, H5’), 7.75-7.84 (3H, m, H6, H7 and H3’), 7.94 
(1H, dd, J 7.6, 1.3, H5 or H8), 7.99 (1H, dd, J 7.6, 1.3, H5 or H8); 
δC (125 MHz, DMSO-d6) 110.7, 111.8, 125.8, 126.4, 130.8, 
132.0, 133.0, 133.0, 134.1, 144.6, 154.0, 176.5, 179.4; m/z (ESI-) 
336 ([M(35Cl)-H]-, 100%), 338 ([M(37Cl)-H]-, 33%); HRMS 
(ESI-) C14H7ClNO5S- ([M(35Cl)-H]-) requires 335.9739, found 
335.9748. 
 
4.1.29. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-1-
phenylmethanesulfonamide (40) 
Following Representative Procedure 1, using 2,3-
dichloronaphthalene-1,4-dione 7 (500 mg, 2.20 mmol), α-
toluenesulfonamide (317 mg, 2.20 mmol) and Cs2CO3 (1000 mg, 
3.08 mmol) in DMF (5 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 80:20) 
gave sulfonamide 40 as a yellow solid (643 mg, 81%). mp 176-
179 °C;  υmax (neat) 3259 (N-H), 1709 (C=O), 1663 (C=O); δH 
(400 MHz, CDCl3) 5.07 (2H, s, CH2Ph), 6.78 (1H, br. s, NH), 
7.39-7.46 (3H, m, H3’, H4’ and H5’), 7.51-7.58 (2H, m, H2’ and 
H6’), 7.77-7.85 (2H, m, H6 and H7), 8.14-8.22 (2H, m, H5 and 
H8); δC (100 MHz, CDCl3) 61.2, 127.4, 127.5, 128.3, 128.9, 
129.2, 129.6, 130.5, 131.0, 131.2, 134.3, 134.9, 141.0, 176.9, 
178.6; m/z (ESI-) 360 ([M(35Cl)-H]-, 100%), 362 ([M(37Cl)-H]-, 
33%); HRMS (ESI+) C17H12ClNNaO4S+ ([M(35Cl)+Na]+) requires 
384.0068, found 384.0068. 
 
4.1.30. N-(3-(3’,5’-Dimethylphenylamino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)methanesulfonamide (41) 
Following Representative Procedure 2, using 
naphthoquinone 31 (100 mg, 0.35 mmol), 3,5-dimethylaniline 
(131 µL, 1.05 mmol) and CeCl3.7H2O (131 mg, 0.35 mmol) in 
MeOH (10 mL). Purification via column chromatography on 
silica gel (eluent pet ether:acetone 80:20) gave 3-
anilinonaphthoquninone 41 as a red solid (84 mg, 65%). mp 84-
92 °C; HPLC (method A) tR 24 min., >99%; υmax (neat) 3294    
(N-H), 1710 (C=O), 1673 (C=O); δH (500 MHz, DMSO-d6) 2.24 
(6H, s, 2 x Ar-Me), 2.63 (3H, s, -SO2Me), 6.71 (3H, s, H2’, H4’ 
and H6’), 7.81 (1H, app. td, J 7.6, 1.3, H6), 7.88 (1H, app. td, J 
7.6, 1.3, H7), 8.01-8.06 (2H, m, H5 and H8), 8.54 (1H, s, 
sulfonamide-NH), 8.83 (1H, s, aniline-NH); δC (125 MHz, 
DMSO-d6) 20.9, 41.1, 114.9, 121.2, 125.4, 125.9, 126.2, 130.5, 
131.8, 133.1, 134.9, 136.6, 138.3, 141.4, 179.5, 182.3; m/z (ESI+) 
393 ([M(35Cl)+Na]+, 100%); HRMS (ESI+) C19H19N2NaO4S+ 
([M(35Cl)+Na]+) requires 393.0879, found 393.0868; λmax (pH 8) 
491 nm (εN 10060 M-1cm-1), λmax (pH 13.75) 578 nm (εCB 
6770 M-1cm-1); pKa 9.5. 
 
4.1.31. N-(3-((3’’,5’’-Dimethylphenyl)amino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)cyclohexanesulfonamide (42) 
Following Representative Procedure 2, using 
naphthoquinone 32 (100 mg, 0.28 mmol), 3,5-dimethylaniline 
(106 µL, 0.85 mmol) and CeCl3.7H2O (105 mg, 0.28 mmol) in 
MeOH (5 mL). Purification via column chromatography on silica 
gel (eluent pet ether:acetone 90:10) and subsequent 
recrystallization from toluene gave 3-anilinonaphthoquninone 42 
as a red solid (40 mg, 32%). mp 192-197 °C (toluene); HPLC 
(method A) tR 20 min., 97%; υmax (neat) 3280 (N-H), 1711 
(C=O), 1670 (C=O); δH (500 MHz, CDCl3) 0.98-1.17 (3H, m, 
H3’, H4’ and H5’), 1.41 (2H, m, H2’ and H6’), 1.62 (1H, app. d, J 
12.6, H4’), 1.77-1.83 (2H, m, H3’ and H5’), 2.02 (2H, app. d, J 
12.1, H2’ and H6’), 2.14 (1H, m, H1’), 2.32 (6H, s, 2 x Ar-Me), 
6.53 (1H, s, sulfonamide-NH), 6.69 (2H, s, H2’’ and H6’’), 6.85 
(1H, s, H4’’), 7.69 (1H, app. td, J 7.6, 1.3, H6), 7.76 (1H, app. td, J 
7.6, 1.3, H7), 7.81 (1H, s, aniline-NH), 8.10 (1H, dd, J 7.6, 1.3, 
H5), 8.15 (1H, dd, J 7.6, 1.3, H8); δC (125 MHz, CDCl3) 21.3, 
25.0, 25.0, 25.8, 61.4, 115.0, 121.1, 126.7, 126.8, 126.9, 130.5, 
131.7, 133.1, 134.8, 136.8, 137.0, 138.1, 180.1, 182.1; m/z (ESI-) 
303 (40%), 437 ([M-H]-, 100%), 438 (40%); HRMS (ESI-) 
C24H25N2O4S- ([M-H]-) requires 437.1541, found 437.1536; λmax 
(pH 8) 505 nm (εN 19850 M-1cm-1), λmax (pH 13.75) 558 nm (εCB 
6790 M-1cm-1); pKa 10.6. 
 
4.1.32. N-(3-(3’’,5’’-Dimethylphenylamino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)-2’-methylbenzenesulfonamide (43) 
Following Representative Procedure 2, using 
naphthoquinone 33 (100 mg, 0.28 mmol), 3,5-dimethylaniline 
(103 µL, 0.83 mmol) and CeCl3.7H2O (103 mg, 0.28 mmol) in 
MeOH (10 mL). Purification via column chromatography on 
silica gel (eluent pet ether:acetone 80:20) gave 3-
anilinonaphthoquninone 43 as a red solid (61 mg, 49%). mp 213-
217 °C; HPLC (method A) tR 20 min., 98%; υmax (neat) 3293    
(N-H), 1671 (C=O), 1613 (C=O); δH (500 MHz, DMSO-d6) 2.19 
(6H, s, 2 x aniline-Me), 2.34 (3H, s, sulfonamide-Me), 6.42 (2H, 
s, H2’’ and H6’’), 6.61 (1H, s, H4’’), 7.09 (1H, d, J 7.4, H3’), 7.16 
(1H, app. t, J 7.4, H5’), 7.36 (1H, app. td, J 7.5, 0.9, H4’), 7.53 
(1H, d, J 7.5, H6’), 7.78 (1H, app. td, J 7.6, 1.3, H6 or H7), 7.84 
(1H, app. td, J 7.6, 1.3, H6 or H7), 7.92 (1H, m, H5 or H8), 8.02 
(1H, m, H5 or H8), 8.60 (1H, s, -NH), 9.03 (1H, s, -NH); δC (125 
MHz, DMSO-d6) 20.1, 21.0, 114.4, 120.1, 125.0, 125.4, 125.8, 
126.2, 127.8, 130.2, 131.6, 131.8, 131.8, 133.0, 135.0, 136.4, 
137.0, 137.7, 139.3, 141.6, 179.4, 182.5; m/z (ESI+) 469 
([M(35Cl)+Na]+, 100%); HRMS (ESI+) C25H23N2NaO4S+ 
([M(35Cl)+Na]+) requires 469.1192, found 469.1179; λmax (pH 8) 
512 nm (εN 11250 M-1cm-1), λmax (pH 13.75) 529 nm (εCB 
6430 M-1cm-1); pKa 9.3. 
 
4.1.33. N-(3-(3’’,5’’-Dimethylphenylamino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)-2’-nitrobenzenesulfonamide (44) 
Following Representative Procedure 2, using 
naphthoquinone 34 (100 mg, 0.26 mmol), 3,5-dimethylaniline 
(95 µL, 0.76 mmol) and CeCl3.7H2O (95 mg, 0.26 mmol) in 
MeOH (10 mL). Purification via column chromatography on 
silica gel (eluent pet ether:acetone 80:20) gave 3-
  
anilinonaphthoquninone 44 as a red solid (24 mg, 20%). mp 257-
263 °C; HPLC (method A) tR 20 min., 96%; υmax (neat) 3297    
(N-H), 1674 (C=O), 1613 (C=O); δH (500 MHz, CDCl3) 2.32 
(6H, s, 2 x Ar-Me), 6.74 (2H, s, H2’’ and H6’’), 6.83 (1H, s, H4’’), 
7.52-7.55 (1H, m, H5’), 7.56 (1H, s, sulfonamide-NH), 7.63-7.73 
(3H, m, H6, H7 and H4’), 7.78 (1H, dd, J 7.9, 1.6, H6’), 7.90-7.93 
(2H, m, H8 and H3’), 7.94 (1H, s, aniline–NH), 8.13 (1H, dd, 
J 7.4, 1.4, H5); δC (125 MHz, CDCl3) 21.3, 111.9, 121.9, 125.6, 
126.6, 126.9, 127.7, 130.2, 130.2, 131.9, 132.7, 132.9, 133.3, 
134.5, 135.1, 136.5, 138.2, 140.3, 147.3, 179.4, 182.1; m/z (ESI-) 
476 ([M(35Cl)-H]-, 100%); HRMS (ESI-) C24H20N3NaO6S- 
([M(35Cl)-H]-) requires 476.0922, found 476.0903; λmax (pH 8) 
528 nm (εN 12380 M-1cm-1), λmax (pH 13.75) 560 nm (εCB 
7610 M-1cm-1); pKa 7.9. 
 
4.1.34. N-(3-((3’’,5’’-Dimethylphenyl)amino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)-2’,6’-difluorobenzenesulfonamide 
(45) 
Following Representative Procedure 2, using 
naphthoquinone 35 (200 mg, 0.52 mmol), 3,5-dimethylaniline 
(195 µL, 1.57 mmol) and CeCl3.7H2O (194 mg, 0.52 mmol) in 
MeOH (5 mL). Purification via column chromatography on silica 
gel (eluent pet ether:EtOAc 85:15) and subsequent 
recrystallization from toluene gave 3-anilinonaphthoquninone 45 
as a red solid (81 mg, 33%). mp 222-225 °C (toluene); HPLC 
(method A) tR 22 min., 98%; υmax (neat) 3347 (N-H), 3249 (N-H), 
1679 (C=O), 1613 (C=O); δH (500 MHz, CDCl3) 2.30 (6H, s, 2 x 
Ar-Me), 6.69 (2H, s, H2’’ and H6’’), 6.72 (1H, s, H4’’), 6.87-6.92 
(2H, m, H3’ and H5’), 7.03 (1H, s, sulfonamide-NH), 7.37-7.43 
(1H, m, H4’), 7.67 (1H, app. td, J 7.5, 1.4, H6), 7.71 (1H, app. td, 
J 7.5, 1.4, H7), 7.87 (1H, s, aniline-NH), 8.00 (1H, dd, J 7.5, 1.4, 
H8), 8.11 (1H, dd, J 7.5, 1.4, H5); δF (470 MHz, CDCl3) -106.6; 
δC (125 MHz, CDCl3) 21.3, 112.0, 112.6 (dd, J 22.9, 3.9), 113.1 
(dd, J 23.1, 3.7), 121.4, 126.6, 126.9, 127.4, 130.3, 131.6, 133.0, 
134.2 (m), 135.0, 136.3, 137.9, 138.9, 159.3 (dd, J 258.5, 3.8), 
179.4, 181.9; m/z (ESI+) 491 ([M+Na]+, 100%); HRMS (ESI+) 
C24H19FN2NaO4S+ ([M+Na]+) requires 491.0848, found 
491.0842; λmax (pH 8) 509 nm (εN 7420 M-1cm-1), λmax (pH 13.75) 
548 nm (εCB 7780 M-1cm-1); pKa 8.4. 
 
4.1.35. N-(3-((3’’,5’’-Dimethylphenyl)amino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)-3’-nitrobenzenesulfonamide (46) 
Following Representative Procedure 2, using 
naphthoquinone 36 (175 mg, 0.43 mmol), 3,5-dimethylaniline 
(162 µL, 1.23 mmol) and CeCl3.7H2O (162 mg, 0.43 mmol) in 
MeOH (5 mL). Purification via column chromatography on  
silica gel (eluent pet ether:EtOAc 80:20) gave 3-
anilinonaphthoquninone 46 as a red solid (59 mg, 26%). mp 216-
221 °C; HPLC (method A) tR 22 min., 96%; υmax (neat) 3290    
(N-H), 1708 (C=O), 1675 (C=O); δH (500 MHz, CDCl3) 2.30 
(6H, s, 2 x Ar-Me), 6.63 (2H, s, H2’’ and H6’’), 6.78 (1H, s, H4’), 
6.90 (1H, s, sulfonamide-NH), 7.55 (1H, app. t, J 8.0, H5’), 7.68 
(1H, app. td, J 7.6, 1.3, H6), 7.72 (1H, app. td, J 7.6, 1.3, H7), 
7.89 (1H, s, aniline-NH), 7.93 (1H, dd, J 7.6, 1.3, H8), 7.98-8.01 
(1H, ddd, J 8.0, 1.9, 0.9, H6’), 8.12 (1H, dd, J 7.6, 1.3, H5), 8.30 
(1H, ddd, J 8.0, 1.9, 0.9, H4’), 8.45 (1H, app. t, J 1.9, H2’); δC 
(125 MHz, CDCl3) 21.3, 112.0, 121.0, 122.5, 126.5, 127.0, 
127.1, 127.3, 129.7, 130.2, 131.5, 132.6, 133.2, 135.2, 136.5, 
138.2, 139.2, 141.6, 147.7, 179.5, 181.8; m/z (ESI-) 476 ([M-H]-, 
100%); HRMS (ESI-) C24H18N3O6S- ([M-H]-) requires 476.0922, 
found 476.0922; λmax (pH 8) 509 nm (εN 8730 M-1cm-1), λmax (pH 
13.75) 551 nm (εCB 5670 M-1cm-1); pKa 8.6. 
 
 
 
4.1.36. N-(3-((3’’,5’’-Dimethylphenyl)amino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)-4’-methylbenzenesulfonamide (47) 
Following Representative Procedure 2, using 
naphthoquinone 37 (200 mg, 0.58 mmol), 3,5-dimethylaniline 
(214 µL, 1.73 mmol) and CeCl3.7H2O (214 mg, 0.58 mmol) in 
toluene (10 mL) at 110 °C. Purification via column 
chromatography on silica gel (eluent pet ether:EtOAc 80:20) 
gave 3-anilinonaphthoquninone 47 as a red solid (64 mg, 25%). 
mp 172-173 °C; HPLC (method A) tR 22 min., 96%; υmax (neat) 
3260 (N-H), 1672 (C=O), 1597 (C=O); δH (500 MHz, CDCl3) 
2.32 (6H, s, 2 x aniline-Me), 2.33 (3H, s, sulfonamide-Me), 6.68 
(2H, s, H2’’ and H6’’), 6.80 (1H, s, sulfonamide-NH), 6.83 (1H, s, 
H4’’), 7.14 (2H, d, J 8.0, H3’ and H5’), 7.56 (2H, d, J 8.0, H2’ and 
H6’), 7.63-7.71 (2H, m, H6 and H7), 7.91 (1H, dd, J 7.4, 1.3, H8), 
8.04 (1H, s, aniline-NH), 8.06 (1H, dd, J 7.4, 1.3, H5); δC 
(125 MHz, CDCl3) 21.4, 21.5, 113.8, 121.0, 126.4, 126.9, 126.9, 
127.3, 129.3, 130.6, 131.4, 133.0, 134.7, 135.9, 137.5, 138.0, 
139.0, 143.9, 179.1, 181.9; m/z (ESI-) 445 ([M-H]-, 100%); 
HRMS (ESI+) C25H22N2O4SNa+ ([M+Na]+) requires 469.1192, 
found 469.1190; λmax (pH 8) 505 nm (εN 14040 M-1cm-1), λmax 
(pH 13.75) 578 nm (εCB 7170 M-1cm-1); pKa 9.7. 
 
4.1.37. N-(3-((3’’,5’’-Dimethylphenyl)amino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)-4’-fluorobenzenesulfonamide (48) 
Following Representative Procedure 2, using 
naphthoquinone 38 (200 mg, 0.55 mmol), 3,5-dimethylaniline 
(205 µL, 1.64 mmol) and CeCl3.7H2O (204 mg, 0.55 mmol) in 
MeOH (10 mL). Purification via column chromatography on 
silica gel (eluent pet ether:acetone 80:20) and subsequent 
recrystallization from toluene gave 3-anilinonaphthoquninone 48 
as a red solid (146 mg, 59%). mp 211-217 °C (toluene); HPLC 
(method A) tR 22 min., 96%; υmax (neat) 3278 (N-H), 1674 
(C=O), 1595 (C=O); δH (500 MHz, CDCl3) 2.32 (6H, s, 2 x 
Ar-Me), 6.67 (2H, s, H2’’ and H6’’), 6.77 (1H, s, sulfonamide-NH), 
6.84 (1H, s, H4’’), 6.98-7.03 (2H, m, H3’ and H5’), 7.65-7.73 (4H, 
m, H6, H7, H2’ and H6’), 7.91-7.94 (1H, m, H8), 7.97 (1H, s, 
aniline-NH), 8.07-8.10 (1H, m, H5); δF (470 MHz, CDCl3) 
-104.5;
 
δC (125 MHz, CDCl3) 21.3, 112.8, 115.9 (d, J 11.5), 
121.1, 126.4, 126.9, 127.0, 130.1 (d, J 9.5), 130.4, 131.4, 133.1, 
134.9, 135.0 (d, J 2.8), 137.1, 138.0, 139.1, 165.2 (d, J 255.1), 
179.2, 181.9; m/z (ESI-) 449 ([M-H]-, 100%); HRMS (ESI-) 
C24H18FN2O4S- ([M-H]-) requires 449.0977, found 449.0967; λmax 
(pH 8) 497 nm (εN 6580 M-1cm-1), λmax (pH 13.75) 546 nm (εCB 
3490 M-1cm-1); pKa 9.9. 
 
4.1.38. N-(3-((3’’,5’’-Dimethylphenyl)amino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)furan-2’-sulfonamide (49) 
Following Representative Procedure 2, using 
naphthoquinone 39 (200 mg, 0.49 mmol), 3,5-dimethylaniline 
(222 µL, 1.78 mmol) and CeCl3.7H2O (222 mg, 0.49 mmol) in 
MeOH (5 mL). Purification via column chromatography on silica 
gel (eluent pet ether:acetone 90:10) and subsequent 
recrystallization from toluene gave 3-anilinonaphthoquninone 49 
as a red solid (164 mg, 66%). mp 205-206 °C (toluene); HPLC 
(method A) tR 23 min., 96%; υmax (neat) 3273 (N-H), 1674 
(C=O), 1596 (C=O); δH (500 MHz, DMSO-d6) 2.25 (6H, s, 2 x 
Ar-Me), 6.46-6.48 (1H, dd, J 3.5, 1.8, H4’), 6.69 (2H, s, H2’’ and 
H6’’), 6.72 (1H, s, H4’’), 6.79 (1H, dd, J 3.5, 0.9, H5’), 7.75-7.81 
(2H, m, H6 and H3’), 7.84 (1H, app. td, J 7.5, 1.3, H7), 7.86-7.89 
(1H, m, H8), 8.03 (1H, dd, J 7.5, 1.3, H5), 8.94 (1H, s, aniline-
NH), 9.31 (1H, s, sulfonamide-NH); δC (125 MHz, DMSO-d6) 
21.0, 111.0, 112.2, 115.0, 121.5, 125.7, 125.7, 126.2, 130.3, 
131.6, 133.0, 135.0, 136.4, 138.1, 142.8, 146.4, 149.1, 178.9, 
182.3; m/z (ESI+) 445 ([M+Na]+, 100%); HRMS (ESI+) 
C22H18N2NaO5S+ ([M+Na]+) requires 445.0829, found 445.0819; 
  
λmax (pH 8) 509 nm (εN 7770 M-1cm-1), λmax (pH 13.75) 541 nm 
(εCB 8440 M-1cm-1); pKa 8.3. 
 
4.1.39. N-(3-((3’’,5’’-Dimethylphenyl)amino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)- 1-phenylmethanesulfonamide (50) 
Following Representative Procedure 2, using 
naphthoquinone 40 (100 mg, 0.28 mmol), 3,5-dimethylaniline 
(103 µL, 0.83 mmol) and CeCl3.7H2O (103 mg, 0.28 mmol) in 
MeOH (5 mL). Purification via column chromatography on silica 
gel (eluent pet ether:acetone 85:15) and subsequent 
recrystallization from toluene gave 3-anilinonaphthoquninone 50 
as a red solid (66 mg, 53%). mp 152-156 °C (toluene); HPLC 
(method A) tR 25 min., 96%; υmax (neat) 3279 (N-H), 1708 
(C=O), 1671 (C=O); δH (500 MHz, DMSO-d6) 2.23 (6H, s, 2 x 
Ar-Me), 4.06 (2H, s, -CH2Ph), 6.71 (1H, s, H4’’), 6.73 (2H, s, H2’’ 
and H6’’), 7.24-7.27 (2H, m, H2’ and H6’), 7.27-7.33 (3H, m, H3’, 
H4’ and H5’), 7.82 (1H, app. td, J 7.6, 1.3, H6), 7.90 (1H, app. td, J 
7.6, 1.3, H7), 8.04 (1H, dd, J 7.6, 1.3, H5), 8.08 (1H, dd, J 7.6, 
1.3, H8), 8.55 (1H, s, sulfonamide-NH), 8.86 (1H, s, aniline-NH); 
δC (125 MHz, DMSO-d6) 20.9, 58.6, 115.1, 121.3, 125.4, 126.0, 
126.2, 128.0, 128.2, 129.6, 130.5, 130.9, 131.8, 133.1, 134.9, 
136.7, 138.3, 141.1, 179.6, 182.3; m/z (ESI-) 445 ([M-H]-, 
100%); HRMS (ESI+) C25H22N2NaO4S+ ([M+Na]+) requires 
469.1192, found 469.1190; λmax (pH 8) 507 nm (εN               
17580 M-1cm-1), λmax (pH 13.75) 568 nm (εCB 6660 M-1cm-1); pKa 
10.0. 
 
4.1.40. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)acetamide (52)36a 
2-amino-3-chloronaphthalene-1,4-dione 51 (500 mg, 
2.41 mmol) and 3 drops conc. H2SO4 were added to a microwave 
vial containing acetyl chloride (5 mL). The vial was sealed and 
the solution stirred at 50 °C for 1 h. The solution was then cooled 
to 0 °C and quenched by the dropwise addition of EtOH until gas 
liberation ceased, before being partitioned between 1 M HCl (30 
mL) and EtOAc (30 mL). The organic layer was collected, 
washed with brine (3 x 20 mL), dried, filtered and concentrated 
in vacuo to give the crude reaction mixture. Purification via 
column chromatography on silica gel (eluent pet ether:EtOAc 
90:10) gave amide 52 as a yellow solid (489 mg, 81%). mp 215-
218 °C (lit. 219-220 °C)36a; δH (500 MHz, DMSO-d6) 2.14 (3H, s, 
CO-Me), 7.87-7.94 (2H, m, H6 and H7), 8.02-8.06 (1H, m, H8), 
8.06-8.10 (1H, m, H5), 10.17 (1H, s, NH); m/z (ESI-) 248 
([M(35Cl)-H]-, 100%). 
 
4.1.41. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)benzamide (53)36a 
2-amino-3-chloronaphthalene-1,4-dione 51 (1.00 g, 
4.82 mmol) was stirred in a microwave vial under N2 with 
sodium hydride (as a 60% dispersion in oil, 636 mg, 15.89 mmol) 
in anhydrous THF (10 mL) at RT for 30 min. Benzoyl chloride 
(721 µL, 6.26 mmol) was added and stirring continued under N2 
at RT for 1 h. EtOH was added dropwise until gas liberation 
ceased, and the solution partitioned between sat. aq. NH4Cl (30 
mL) and EtOAc (30 mL). The organic layer was collected, 
washed with brine (3 x 20 mL), dried, filtered and concentrated 
in vacuo to give the crude product. Purification via column 
chromatography on silica gel (eluent pet ether:acetone 95:5) gave 
amide 53 as a beige solid (1.042 g, 69%). mp 183-185 °C (lit. 
254-256 °C)36a; δH (400 MHz, DMSO-d6) 7.55-7.60 (2H, m, H3’ 
and H5’), 7.65-7.69 (1H, m, H4’), 7.91-7.96 (2H, m, H6 and H7), 
8.01-8.05 (2H, m, H2’ and H6’), 8.07-8.10 (1H, m, H5 or H8), 
8.12-8.15 (1H, m, H5 or H8), 10.49 (1H, s, NH); m/z (ESI-) 310 
([M(35Cl)-H]-, 100%). 
 
4.1.42. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)phenylacetamide (54)36a 
Method A: 2-amino-3-chloronaphthalene-1,4-dione 51 
(2.50 g, 12.04 mmol) was stirred in phenyl acetyl chloride 
(12.5 mL). HCl gas, produced in situ by the dropwise addition of 
c.H2SO4 onto NaCl (20 g), was bubbled through the reaction 
mixture for 15 min. After the removal of the gas inlet, the 
reaction mixture was heated to reflux under a gaseous HCl 
atmosphere for 2 h. The solution was cooled to RT and EtOH 
was added dropwise until gas liberation ceased. The solution was 
then partitioned between sat. aq. NH4Cl (100 mL) and EtOAc 
(100 mL). The organic layer was collected, washed with brine 
(3 x 50 mL), dried, filtered and concentrated in vacuo. 
Purification via column chromatography on silica gel (eluent pet 
ether:acetone 90:10) gave phenylacetamide 54 as a beige solid 
(549 mg, 14%).  
Method B: 2-amino-3-chloro-1,4-naphthoquinone 51 
(100 mg, 0.44 mmol), 2-phenylacetamide (71 mg, 0.53 mmol), 
Pd(OAc)2 (1 mg, 0.004 mmol), Xantphos (4 mg, 0.007 mmol) 
and KOtBu (74 mg, 0.66 mmol) were stirred in 1,4-dioxane 
(1 mL) in a sealed microwave vial under argon and heated to 
80 °C for 16 h. The solution was cooled to RT and partitioned 
between EtOAc (30 mL) and sat. aq. NH4Cl (30 mL). The 
organic layer was collected, washed with brine (3 x 20 mL), 
dried, filtered and concentrated in vacuo to give the crude 
product. Purification via column chromatography on silica gel 
(eluent pet ether:EtOAc 75:25) gave phenylacetamide 54 as a 
beige solid (13 mg, 9%). 
Method C: 2-amino-3-chloro-1,4-naphthoquinone 51 (2.00 g, 
9.63 mmol) was stirred in toluene (25 mL) in a 2-necked round-
bottomed flask at 90 °C. To a pressure-equalised dropping funnel 
was added phenylacetyl chloride (5.97 mL, 38.53 mmol) and 
boron trifluoride diethyl etherate (1.16 mL, 7.11 mmol) in 
toluene (15 mL). This solution was added dropwise to the 
reaction flask over a period of 30 min. and the reaction mixture 
was stirred at 90 °C for a further 4 h. The reaction mixture was 
cooled to RT and then concentrated in vacuo. Acetone (20 mL) 
was added to the reaction mixture and the beige precipitate that 
formed was collected by suction filtration. This precipitate was 
washed three further times with cold acetone (3 x 10 mL) to give 
phenylacetamide 54 as a beige solid (1.781 g, 57%). mp 205-
209 °C (lit. 207-208 °C)36a; δH (400 MHz, CDCl3) 3.86 (2H, s,             
-CH2Ph), 7.29-7.48 (3H, m, H2’’, H3’’ and H4’’), 7.62 (1H, br. s, 
NH), 7.76 (2H, m, H6 and H7), 8.05-8.09 (1H, m, H5), 8.15-8.19 
(1H, m, H8); m/z (ESI+) 348 ([M(35Cl)+Na]+, 100%). 
 
4.1.43. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)hydrocinnanamide (55) 
2-amino-3chloro-1,4-naphthoquinone 51 (1.70 g, 8.19 mmol) 
and hydrocinnamoyl chloride (5.0 mL, 30.13 mmol) were stirred 
in BF3.OEt2 (1.0 mL) in a round bottomed flask and heated to 
reflux for 30 min. The reaction mixture was then cooled and 
toluene (10 mL) was added, before being heated to reflux for a 
further 24 h. The crude reaction mixture was concentrated in 
vacuo and the subsequent addition of acetone (20 mL) resulted in 
the precipitation of a yellow solid. This solid was collected by 
suction filtration and recrystallized from boiling acetone to give 
hydrocinnanamide 55 as a yellow solid (1.39 g, 50%). mp 162-
167 °C; υmax (neat) 3284 (N-H), 1662 (C=O); δH (500 MHz, 
CDCl3) 2.84 (2H, t, J 7.6, CO-CH2-CH2Ph), 3.09 (2H, t, J 7.6, 
Ph-CH2-CH2CO), 7.21-7.28 (3H, m, H2’, H4’ and H6’), 7.30-7.34 
(2H, m, H3’ and H5’), 7.61 (1H, s, NH), 7.74-7.81 (2H, m, H6 and 
H7), 8.10 (1H, dd, J 7.3, 1.5, H8), 8.19 (1H, dd, J 7.3, 1.5, H5); δC 
(125 MHz, CDCl3) 31.1, 38.9, 126.5, 127.0, 127.5, 128.4, 128.7, 
130.2, 131.5, 133.2, 134.1, 134.8, 138.9, 139.9, 168.8, 177.6, 
179.8; m/z (ESI-) 113 (30%), 249 (40%), 338 ([M(35Cl)-H]-, 
  
100%); HRMS C19H14ClNNaO3+ ([M(35Cl)+Na]+) requires 
362.0554, found 362.0554. 
 
4.1.44. N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-1-
phenylcyclopropanecarboxamide (58) 
1-phenyl-1cyclopropanecarboxylic acid 56 (3.12 g, 
19.27 mmol) and DMF (3 drops) were stirred in anhydrous 
CH2Cl2 (10 mL) at RT. Oxalyl chloride (1.83 mL, 19.27 mmol) 
was added to this solution and stirring continued at RT for 3 h. 
The reaction mixture was then concentrated in vacuo. 2-amino-3-
chloro-1,4-naphthoquinone 51 (1.00 g, 4.82 mmol), boron 
trifluoride diethyl etherate (0.81 mL, 4.82 mmol) and toluene 
(15 mL) were added and the mixture was stirred at 90 °C for 
30 min. and subsequently at 110 °C for 1 h. The crude reaction 
mixture was concentrated in vacuo and the subsequent addition 
of acetone (20 mL) resulted in the precipitation of a yellow solid. 
This solid was collected by suction filtration and washed with 
cold acetone (2 x 10 mL) to give phenylcyclopropane-
carboxamide 58 as a yellow solid (1.354 g, 80%). mp 214-
215 °C; υmax (neat) 3338 (N-H), 1739 (C=O), 1713 (C=O), 1665 
(C=O); δH (500 MHz, DMSO-d6) 1.22-1.25 (2H, m, 2 x 
cyclopropyl-CH), 1.51-1.54 (2H, m, 2 x cyclopropyl-CH), 7.33-
7.38 (1H, m, H4’), 7.40-7.45 (2H, m, H3’ and H5’), 7.49-7.53 (2H, 
m, H2’ and H6’), 7.87-7.92 (2H, m, H6 and H7), 7.99-8.03 (1H, m, 
H8), 8.05-8.08 (1H, m, H5), 8.55 (1H, s, NH); δC (125 MHz, 
DMSO-d6) 16.0, 31.0, 126.6, 126.8, 127.8, 128.9, 130.1, 130.5, 
130.9, 134.4, 134.6, 134.7, 138.9, 140.9, 170.9, 177.6, 178.8;  
m/z (ESI+) 199 (100%), 352 ([M(35Cl)+H]+, 40%), 374 
([M(35Cl)+Na]+, 60%), 376 ([M(37Cl)+Na]+, 20%); HRMS (ESI+) 
C20H14ClNNaO3+ ([M(35Cl)+Na]+) requires 374.0554, found 
374.0549. 
 
4.1.45. N-(3-(3’’,5’’-Dimethylphenylamino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)acetamide (59) 
Following Representative Procedure 2, using 
naphthoquinone 52 (101 mg, 0.41 mmol), 3,5-dimethylaniline 
(151 µL, 1.21 mmol) and CeCl3.7H2O (151 mg, 0.41 mmol) in 
MeOH (5 mL). Purification via column chromatography on  
silica gel (eluent pet ether:acetone 80:20) gave 3-
anilinonaphthoquinone 59 as a dark red solid (57 mg, 42%). 
mp 231-234 °C; HPLC (method A) tR 23 min., 97%; υmax (neat) 
3291 (N-H), 1667 (C=O), 1638 (C=O); δH (400 MHz, DMSO-d6) 
1.36 (3H, s, CO-Me), 2.22 (6H, s, 2 x Ar-Me), 6.56 (2H, s, H2’ 
and H6’), 6.69 (1H, s, H4’), 7.78 (1H, app. td, J 7.5, 1.4, H6), 7.85 
(1H, app. td, J 7.3, 1.3, H7), 8.00 (1H, dd, J 7.6, 1.0, H8), 8.03 
(1H, dd, J 7.6, 1.3, H5), 8.84 (1H, s, aniline-NH), 9.19 (1H, br. s, 
amide-NH); δC (100 MHz, DMSO-d6) 20.9, 21.7, 115.4, 120.9, 
124.9, 125.7, 126.1, 130.2, 131.9, 133.0, 134.9, 136.2, 137.3, 
165.9, 179.1, 182.5; m/z (ESI+) 357 ([M+Na]+, 100%); HRMS 
(ESI+) C20H18N2NaO3+ ([M+Na]+) requires 357.1210, found 
357.1198. 
 
4.1.46. N-(3-(3’’,5’’-Dimethylphenylamino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzamide (60) 
tBuOH (0.63 mL) and H2O (0.2 µL, 0.013 mmol) were sealed 
in a vessel under argon. Pd(OAc)2 (0.9 mg, 0.003 mmol) and 
XPhos (5.5 mg, 0.01 mmol) were added and the resulting light 
yellow mixture was heated under argon to 110 °C for 3 min. until 
it became dark brown. This solution was then syringed into a 
vessel containing naphthoquinone 53 (100 mg, 0.32 mmol), 3,5-
dimethylaniline (48 µL, 0.39 mmol) and K2CO3 (62 mg, 
0.45 mmol) under argon; this vessel was sealed and heated to 
110 °C for 16 h. The solution was cooled to RT, diluted with 
EtOAc (10 mL) and filtered through Celite®. The filtrate was 
then partitioned between EtOAc (30 mL) and sat. aq. NH4Cl 
(20 mL); the organic layer was collected, washed with brine (3 x 
20 mL), dried, filtered and concentrated in vacuo. Purification via 
column chromatography on silica gel (eluent pet ether:EtOAc 
80:20) gave 3-anilinonaphthoquinone 60 as a purple solid (104 
mg, 82%). mp 198-204 °C; HPLC (method A) tR 23 min., 95%; 
υmax (neat) 3303 (N-H), 1667 (C=O), 1595 (C=O); δH (400 MHz, 
CDCl3) 2.16 (6H, s, 2 x Ar-Me), 6.53 (1H, s, H4’’), 6.59 (2H, s, 
H2’’ and H6’’), 7.30-7.36 (2H, m, H3’ and H5’), 7.42-7.47 (1H, m, 
H4’), 7.50-7.55 (2H, m, H2’ and H6’), 7.68 (1H, app. td, J 7.3, 1.5, 
H6 or H7), 7.74 (1H, app. td, J 7.8, 1.3, H6 or H7), 7.94 (1H, s, 
aniline-NH), 8.10-8.15 (2H, m, H5 and H8), 8.34 (1H, br. s, 
amide-NH); δC (100 MHz, CDCl3) 21.1, 115.4, 120.0, 126.0, 
126.4, 126.8, 127.3, 128.2, 130.7, 131.7, 131.9, 133.0, 133.5, 
134.2, 134.6, 137.0, 137.6, 163.8, 180.1, 182.1;  m/z (ESI-) 395 
([M-H]-, 100%); HRMS (ESI+) C25H20N2NaO3+ ([M+Na]+) 
requires 419.1366, found 419.1347. 
 
4.1.47. N-(3-(3’’,5’’-Dimethylphenylamino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)phenylacetamide (61) 
Following Representative Procedure 2, using 
naphthoquinone 54 (80 mg, 0.25 mmol), 3,5-dimethylaniline (92 
µL, 0.74 mmol) and CeCl3.7H2O (92 mg, 0.25 mmol) in MeOH 
(3 mL). Purification via column chromatography on silica gel 
(eluent pet ether:acetone 90:10 to 70:30) and subsequent 
recrystallisation from boiling toluene gave 3-
anilinonaphthoquinone 61 as a purple solid (49 mg, 49%). 
mp 216-217 °C; HPLC (method A) tR 24 min., 98%; υmax (neat) 
3299 (N-H), 1670 (C=O), 1612 (C=O); δH (500 MHz, CDCl3) 
2.31 (6H, s, 2 x Ar-Me), 3.20 (2H, s, -CH2Ph), 6.53 (2H, s, H2’’ 
and H6’’), 6.81 (1H, s, H4’’), 7.03 (2H, d, J 6.9, H2’ and H6’), 7.28-
7.36 (3H, m, H3’, H4’ and H5’), 7.45 (1H, s, amide-NH), 7.65 (1H, 
app. td, J 7.5, 1.1, H6), 7.71 (1H, app. td, J 7.5, 1.1, H7), 7.75 
(1H, s, aniline-NH), 8.05 (1H, dd, J 7.5, 1.1, H8), 8.08 (1H, dd, J 
7.5, 1.1, H5); δC (125 MHz, CDCl3) 21.3, 43.1, 114.8, 120.4, 
126.2, 126.2, 126.7, 127.5, 129.0, 129.6, 130.5, 131.8, 132.9, 
133.8, 134.6, 134.7, 136.9, 137.6, 167.3, 179.9, 182.1;  m/z (ESI-) 
409 ([M-H]-, 100%); HRMS (ESI+) C26H22N2NaO3+ ([M+Na]+) 
requires 433.1523, found 433.1502. 
 
4.1.48. N-(3-((3’’,5’’-Dimethylphenyl)amino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)hydrocinnanamide (62) 
Following Representative Procedure 2, using 
naphthoquinone 55 (100 mg, 0.30 mmol), 3,5-dimethylaniline 
(110 µL, 0.89 mmol) and CeCl3.7H2O (110 mg, 0.30 mmol) in 
methanol (5 mL). Purification via column chromatography on 
silica gel (eluent pet ether:acetone 90:10 to 75:25) gave 3-
anilinonaphthoquinone 62 as a red solid (67 mg, 54%). mp 186-
190 °C; HPLC (method A) tR 23 min., 95%; υmax (neat) 3305    
(N-H), 1669 (C=O), 1596 (C=O); δH (500 MHz, CDCl3) 2.19-
2.24 (2H, m, -CH2CH2Ph), 2.30 (6H, s, 2 x Ar-Me), 2.46-2.51 
(2H, m, -CH2CH2Ph), 6.57 (2H, s, H2’’ and H6’’), 6.78 (1H, s, 
H4’’), 7.06 (2H, app. d, J 7.3, H2’ and H6’), 7.19 (1H, app. t, J 7.3, 
H4’), 7.24-7.29 (2H, m, H3’ and H5’), 7.60 (1H, s, amide-NH), 
7.67 (1H, app. td, J 7.6, 1.3, H6 or H7), 7.73 (1H, app. td, J 7.6, 
1.3, H6 or H7), 7.84 (1H, s, aniline-NH), 8.09-8.12 (2H, m, H5 
and H8); δC (125 MHz, CDCl3) 21.3, 30.8, 37.7, 114.9, 120.1, 
125.9, 126.2, 126.3, 126.7, 128.1, 128.5, 130.6, 131.8, 133.0, 
134.2, 134.6, 136.9, 137.6, 140.6, 168.4, 180.1, 182.1; m/z (ESI+) 
425 ([M+H]+, 45%), 447 ([M+Na]+, 80%), 871 ([2M+H]+, 
100%); HRMS C27H24N2NaO3S+ ([M+Na]+) requires 447.1679, 
found 447.1672. 
 
4.1.49. N-(3-((3’’,5’’-Dimethylphenyl)amino)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)-1-phenylcyclopropanecarboxamide 
(63) 
Following Representative Procedure 2, using 
naphthoquinone 58 (150 mg, 0.43 mmol), 3,5-dimethylaniline 
  
(160 µL, 1.28 mmol) and CeCl3.7H2O (159 mg, 0.43 mmol) in 
MeOH (5 mL). Purification via column chromatography on silica 
gel (eluent pet ether:EtOAc 95:5 to 75:25) gave 3-
anilinonaphthoquinone 63 as a red solid (107 mg, 58%). mp 241-
242 °C; HPLC (method A) tR 23 min., >99%; υmax (neat) 3356 
(N-H), 1734 (C=O), 1669 (C=O); δH (500 MHz, CDCl3) 0.83-
0.86 (2H, m, 2 x cyclopropyl-CH), 1.07-1.10 (2H, m, 2 x 
cyclopropyl-CH), 2.35 (6H, s, 2 x Ar-Me), 6.52 (2H, s, H2’’ and 
H6’’), 6.87 (1H, s, H4’’), 7.25-7.29 (2H, m, H2’ and H6’), 7.35-7.38 
(1H, m, H4’), 7.39-7.44 (2H, m, H3’ and H5’), 7.46 (1H, s, amide-
NH), 7.62 (1H, app. td, J 7.5, 1.3, H6), 7.65-7.70 (2H, m, aniline-
NH and H7), 8.00 (1H, dd, J 7.5, 1.3, H8), 8.05 (1H, dd, J 7.5, 
1.3, H5); δC (125 MHz, CDCl3) 16.3, 21.4, 30.4, 115.5, 120.4, 
126.0, 126.1, 126.6, 128.3, 129.1, 130.5, 131.0, 131.8, 132.8, 
134.3, 134.5, 137.2, 137.6, 139.0, 170.8, 179.9, 182.2; m/z (ESI+) 
437 ([M+H]+, 60%), 459 ([M+Na]+, 100%); HRMS (ESI+) 
C28H24N2NaO3+ ([M+Na]+) requires 459.1679, found 459.1668. 
 
4.1.50. N-(3-(3’’-Formylphenyl)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)benzamide (64) 
Following Representative Procedure 6, using 
naphthoquinone 53 (100 mg, 0.32 mmol), 3-formylphenylboronic 
acid (96 mg, 0.64 mmol), Pd(PPh3)2Cl2 (22 mg, 0.03 mmol) and 
sat. aq. NaHCO3 (2.5 mL) in THF (11 mL). Purification via 
column chromatography on silica gel (eluent pet ether:EtOAc 
85:15) gave 3-arylnaphthoquinone 64 as a yellow-orange solid 
(19 mg, 15%). mp 63-69 °C; HPLC (method A) tR 24 min., 
>99%; υmax (neat) 3307 (N-H), 1694 (C=O), 1663 (C=O); δH 
(500 MHz, CDCl3) 7.41-7.46 (2H, m, H3’ and H5’), 7.52-7.61 
(2H, m, H4’ and H5’’), 7.70-7.74 (2H, m, H2’ and H6’), 7.74-7.78 
(1H, m, H6’’), 7.78-7.87 (3H, m, H6, H7 and H4’’), 7.94-7.97 (1H, 
m, H2’’), 8.18-8.25 (2H, m, H5 and H8), 8.62 (1H, s, NH), 9.98 
(1H, s, CHO); δC (500 MHz, CDCl3) 126.5, 127.2, 127.6, 128.8, 
128.9, 129.7, 130.1, 130.3, 132.1, 132.2, 132.8, 133.2, 133.7, 
134.8, 135.1, 135.4, 136.1, 137.9, 163.7, 182.3, 183.0, 191.9;  
m/z (ESI-) 380 ([M-H]-, 100%); HRMS (ESI+) C24H15NNaO4+ 
([M+Na]+) requires 404.0893, found 404.0890; λmax (pH 8) < 400 
nm, λmax (pH 13.75) 485 nm (εCB 2670 M-1cm-1); pKa 10.9. 
 
4.1.51. N-(3-(Furan-3’’-yl)-1,4-dioxo-1,4-dihydronaphthalen-
2-yl)benzamide (65) 
Following Representative Procedure 6, using 
naphthoquinone 54 (100 mg, 0.32 mmol), 3-furanylboronic acid 
(72 mg, 0.64 mmol), Pd(PPh3)2Cl2 (22 mg, 0.3 mmol) and sat. aq. 
NaHCO3 (2.5 mL) in THF (11 mL). Purification via column 
chromatography on silica gel (eluent pet ether:EtOAc 80:20) 
gave 3-arylnaphthoquinone 65 as a copper brown solid (65 mg, 
59%). mp 202-205 °C; HPLC (method A) tR 24 min., 97%; 
υmax (neat) 3232 (N-H), 1675 (C=O), 1647 (C=O); δH (400 MHz, 
CDCl3) 6.62-6.65 (1H, m, H5’’), 7.35-7.38 (1H, m, H4’’), 7.50-
7.55 (2H, m, H3’ and H5’), 7.59-7.64 (1H, m, H4’), 7.75 (1H, app. 
td, J 7.6, 1.3, H7), 7.79 (1H, app. td, J 7.3, 1.6, H6), 7.90-7.94 
(2H, m, H2’ and H6’), 8.13 (1H, dd, J 7.4, 1.1, H8), 8.19 (1H, dd, 
J 7.6, 1.0, H5), 8.25 (1H, app. s, H2’’), 8.66 (1H, br. s, NH); 
δC (400 MHz, CDCl3) 109.3, 117.3, 126.3, 127.1, 127.6, 127.8, 
129.0, 130.2, 132.6, 132.8, 133.3, 133.6, 134.6, 135.9, 142.5, 
145.8, 164.2, 182.1, 183.2;  m/z (ESI-) 342 ([M-H]-, 100%); 
HRMS (ESI-) C21H12NO4- ([M-H]-) requires 342.0772, found 
342.0782; λmax (pH 8) < 400 nm, λmax (pH 13.75) 513 nm (εCB 
4820 M-1cm-1); pKa 12.1. 
 
4.1.52. N-(3-(3’’-Formylphenyl)-1,4-dioxo-1,4-
dihydronaphthalen-2-yl)phenylacetamide (66) 
Following Representative Procedure 6, using 
naphthoquinone 53 (200 mg, 0.61 mmol), 3-formylphenylboronic 
acid (184 mg, 1.23 mmol), Pd(PPh3)2Cl2 (43 mg, 0.06 mmol) and 
Na2CO3 (194 mg, 1.84 mmol) in toluene (10 mL). Purification 
via column chromatography on silica gel (eluent pet ether:EtOAc 
90:10 to 70:30) gave 3-arylnaphthoquinone 66 as a yellow solid 
(107 mg, 44%). mp 158-162 °C; HPLC (method A) tR 23 min., 
>99%; υmax (neat) 3272 (N-H), 1695 (C=O), 1665 (C=O); δH (500 
MHz, CDCl3) 3.51 (2H, s, -CH2Ph), 7.12 (2H, dd, J 7.4, 1.7, H2’ 
and H6’), 7.31-7.37 (3H, m, H3’, H4’ and H5’), 7.53 (1H, app. t, 
J 7.7, H5’’), 7.58 (1H, app. dt, J 7.7, 1.5, H6’’), 7.72 (1H, app. t, 
J 1.5, H2’’), 7.75 (1H, app. td, J 7.6, 1.3, H7), 7.79 (1H, app. td, 
J 7.6, 1.3, H6), 7.85 (1H, app. dt, J 7.7, 1.5, H4’’), 7.94 (1H, s, 
NH), 8.11 (1H, dd, J 7.6, 1.3, H8), 8.14 (1H, dd, J 7.6, 1.3, H5), 
9.93 (1H, s,  CHO); δC (125 MHz, CDCl3) 44.6, 126.4, 127.1, 
127.8, 128.6, 129.1, 129.2, 129.3, 130.2, 130.2, 132.1, 133.0, 
133.2, 133.8, 134.4, 134.9, 135.6, 136.0, 137.3, 166.9, 182.1, 
183.0, 191.9; m/z (ESI+) 111 (30%), 418 ([M+Na]+, 100%), 434 
(25%); HRMS (ESI-) C25H16NO4- ([M-H]-) requires 394.1085, 
found 394.1076; λmax (pH 8) < 400 nm, λmax (pH 13.75) 451 nm 
(εCB 8490 M-1cm-1); pKa 11.4. 
 
4.1.53. N-(3-(Furan-3’’-yl)-1,4-dioxo-1,4-dihydronaphthalen-
2-yl)phenylacetamide (67) 
Following Representative Procedure 6, using 
naphthoquinone 54 (80 mg, 0.25 mmol), 3-furanylboronic acid 
(55 mg, 0.49 mmol), Pd(PPh3)2Cl2 (18 mg, 0.03 mmol) and sat. 
aq. NaHCO3 (2 mL) in THF (8.8 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 90:10 then 
pet ether:EtOAc 80:20) and recrystallisation from boiling toluene 
gave 3-arylnaphthoquinone 67 as a copper brown solid (8 mg, 
9%). mp 120-124 °C; HPLC (method A) tR 25 min., 97%; 
υmax (neat) 3306 (N-H), 1665 (br., C=O); δH (400 MHz, CDCl3) 
3.71 (2H, s, -CH2Ph), 6.38-6.41 (1H, m, H5’’), 7.33-7.47 (6H, m, 
H2’, H3’, H4’, H5’, H6’ and H4’’), 7.69-7.79 (2H, m, H6 and H7), 
7.86 (1H, s, NH), 8.05-8.09 (2H, m, H2’’ and H5 or H8), 8.13 (1H, 
dd, J 7.5, 1.4, H5 or H8); δC (500 MHz, CDCl3) 44.8, 109.5, 
117.0, 126.2, 127.0, 127.9, 128.4, 129.3, 129.5, 130.3, 132.4, 
133.5, 133.6, 134.5, 135.6, 142.3, 145.6, 167.6, 181.8, 183.2;  
m/z (ESI-) 356 ([M-H]-, 100%); HRMS (ESI+) C22H15NNaO4+ 
([M+Na]+) requires 380.0893, found 380.0883; λmax (pH 8) < 400 
nm, λmax (pH 13.75) 512 nm (εCB 2450 M-1cm-1); pKa 12.5. 
 
4.1.54. N-(3-Chloro-5-nitro-1,4-dioxo-1,4-dihydronaphthalen-
2-yl)benzenesulfonamide (70) 
Following Representative Procedure 1, using 2,3-dichloro-5-
nitronaphthalene-1,4-dione 68 (1.00 g, 3.68 mmol), 
benzenesulfonamide (577 mg, 3.68 mmol) and Cs2CO3 (1.68 g, 
5.15 mmol) in DMF (15 mL). Purification and separation of 
regioisomers via column chromatography on silica gel (eluent pet 
ether:acetone 50:50) gave sulfonamide 70 as a yellow solid 
(556 mg, 38%). mp 220-223 °C; υmax (KBr) 3201 (N-H), 1687 
(br., C=O); δH (400 MHz, DMSO-d6) 7.57-7.65 (2H, m, H2’ and 
H6’ or H3’ and H5’), 7.65-7.71 (1H, m, H4’), 7.94-7.99 (2H, m, H2’ 
and H6’ or H3’ and H5’), 7.99-8.06 (1H, m, H7), 8.14-8.20 (2H, m, 
H6 and H8); δC (100 MHz, DMSO-d6) 122.0, 126.7, 128.1, 129.1, 
129.3, 131.9, 132.9, 135.7, 142.6, 147.9, 174.7, 177.5; m/z (ESI-) 
391 ([M(35Cl)-H]-, 100%); HRMS (ESI-) C16H8ClN2O6S- 
([M-H]-) requires 390.9797, found 390.9797. 
 
4.1.55. N-(3-Chloro-8-nitro-1,4-dioxo-1,4-dihydronaphthalen-
2-yl)benzenesulfonamide (73) 
Following Representative Procedure 1, using 2,3-dichloro-5-
nitronaphthalene-1,4-dione 68 (1.00 g, 3.68 mmol), 
benzenesulfonamide (577 mg, 3.68 mmol) and Cs2CO3 (1.68 g, 
5.15 mmol) in DMF (15 mL). Purification and separation of 
regioisomers via column chromatography on silica gel (eluent pet 
ether:acetone 50:50) gave sulfonamide 73 as a yellow solid 
(405 mg, 28%). mp 222-225 °C; υmax (KBr) 3223 (N-H), 1694 
  
(C=O), 1675 (C=O); δH (400 MHz, DMSO-d6) 7.57-7.65 (2H, m, 
H2’ and H6’ or H3’ and H5’), 7.65-7.71 (1H, m, H4’), 7.87-7.92 
(2H, m, H2’ and H6’ or H3’ and H5’), 8.05 (1H, app. t, J 8.0, H6), 
8.17 (1H, d, J 8.0, H5 or H7), 8.26 (1H, d, J 8.0, H5 or H7); 
δC (100 MHz, DMSO-d6) 122.3, 126.6, 127.9, 129.1, 129.3, 
132.7, 132.9, 135.9, 142.6, 148.1, 175.9, 176.6; m/z (ESI-) 391 
([M(35Cl)-H]-, 100%); HRMS (ESI-) C16H8ClN2O6S- 
([M(35Cl)-H]-) requires 390.9797, found 390.9796. 
 
4.1.56. N-(3-(3’’,5’’-Dimethylphenylamino)-5-nitro-1,4-dioxo-
1,4-dihydronaphthalen-2-yl)benzenesulfonamide (74) 
Following General Procedure 2, using naphthoquinone 70 
(100 mg, 0.26 mmol), 3,5-dimethylaniline (95 µL, 0.77 mmol) 
and CeCl3.7H2O (95 mg, 0.26 mmol) in toluene (10 mL) at 
110 °C. Purification via column chromatography on silica gel 
(eluent pet ether:acetone 75:25) and subsequent trituration using 
hexane gave 3-anilinonaphthoquinone 74 as a purple solid 
(86 mg, 70%). mp 242-244 °C; HPLC (method B) tR 9 min., 
95%; υmax (KBr) 3272 (N-H), 1687 (C=O), 1595 (C=O); 
δH (500 MHz, DMSO-d6) 2.24 (6H, s, 2 x Ar-Me) 6.60 (2H, s, 
H2’’ and H6’’), 6.69 (1H, s, H4’’), 7.37-7.43 (2H, m, H3’ and H5’), 
7.49-7.54 (1H, m, H4’), 7.60-7.65 (2H, m, H2’ and H6’), 7.97 (1H, 
app. t, J 7.9, H7), 8.02 (1H, dd, J 7.9, 1.3, H6 or H8), 8.08 (1H, dd, 
J 7.9, 1.3, H6 or H8), 9.05 (1H, s, NH), 9.24 (1H, s, NH); 
δC (100 MHz, DMSO-d6) 21.8, 115.5, 121.7, 123.1, 126.4, 127.4, 
127.6, 129.1, 129.4, 133.0, 133.3, 136.6, 137.5, 139.2, 141.8, 
144.4, 148.5, 177.5, 180.5; m/z (ESI-) 476 ([M-H]-, 100%); 
HRMS (ESI-) C24H18N3O6S- ([M-H]-) requires 476.0922, found 
476.0917; λmax (pH 8) 555 nm (εN 5360 M-1cm-1), λmax (pH 13.75) 
578 nm (εCB 4520 M-1cm-1); pKa 8.2. 
 
4.1.57. N-(3-(3’’,5’’-Dimethylphenylamino)-6-nitro-1,4-dioxo-
1,4-dihydronaphthalen-2-yl)benzenesulfonamide (75) 
Following Representative Procedure 1, using 2,3-dichloro-6-
nitronaphthalene-1,4-dione 69 (1.00 g, 3.68 mmol), 
benzenesulfonamide (577 mg, 3.68 mmol) and Cs2CO3 (1.68 g, 
5.15 mmol) in DMF (15 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 95:5 to 
80:20) gave a mixture of regioisomeric 6-nitro and 7-nitro 
products, 71 and 72 (788 mg, 55%). Subsequently, following 
Representative Procedure 2, using this regioisomeric mixture 
(788 mg, 2.01 mmol), 3,5-dimethylaniline (751 µL, 6.02 mmol) 
and CeCl3.7H2O (748 mg, 2.01 mmol) in MeOH (5 mL). 
Purification and separation of regioisomers via column 
chromatography (eluent pet ether:EtOAc 95:5 to 85:15) gave 3-
anilinonaphthoquinone 75 as a purple solid (115 mg, 12% over 2 
steps). mp 250-253 °C; HPLC (method A) tR 23 min., >99%; 
υmax (neat) 3460 (N-H), 1653 (br., C=O); δH (500 MHz, CDCl3) 
2.27 (6H, s, 2 x Ar-Me), 6.63 (2H, s, H2’’ and H6’’), 6.67 (1H, s, 
NH), 6.81 (1H, s, H4’’), 7.26-7.32 (2H, m, H3’ and H5’), 7.39-7.46 
(1H, m, H4’), 7.58-7.62 (2H, m, H2’ and H6’), 8.03 (1H, d, J 8.4, 
H8), 8.06 (1H, s, NH), 8.42 (1H, dd, J 8.4, 2.3, H7), 8.80 (1H, d, J 
2.3, H5); δC (125 MHz, CDCl3) 20.3, 113.1, 120.4, 121.0, 126.3, 
126.8, 127.1, 127.8, 127.9, 130.5, 132.2, 134.3, 135.7, 137.2, 
137.6, 138.6, 149.5, 175.9, 179.1;  m/z (ESI-) 476 ([M-H]-, 
100%); HRMS (ESI+) C24H19N3NaO6S ([M+Na]+) requires 
500.0887, found 500.0876; λmax (pH 8) 527 nm (εN 
4500 M-1cm-1), λmax (pH 13.75) 600 nm (εCB 2240 M-1cm-1); pKa 
7.5. 
 
4.1.58. N-(3-(3’’,5’’-Dimethylphenylamino)-7-nitro-1,4-dioxo-
1,4-dihydronaphthalen-2-yl)benzenesulfonamide (76) 
Following an identical procedure to the synthesis of 75 
above, the other regioisomeric product, 3-anilinonaphthoquinone 
76, was obtained by column chromatography as a purple solid 
(121 mg, 13% over 2 steps). mp 253-256 °C; HPLC (method A) 
tR 24 min., 97%; υmax (neat) 3390 (N-H), 1656 (br., C=O); 
δH (500 MHz, DMSO-d6) 2.23 (6H, s, 2 x Ar-Me), 6.63 (2H, s, 
H2’’ and H6’’), 6.70 (1H, s, H4’’), 7.36-7.41 (2H, m, H3’ and H5’), 
7.49-7.54 (1H, m, H4’), 7.57 (2H, dd, J 8.4, 1.1, H2’ and H6’), 8.25 
(1H, d, J 8.5, H5), 8.40 (1H, d, J 2.2, H8), 8.53 (1H, dd, J 8.5, 2.2, 
H6), 9.05 (1H, s, NH), 9.18 (1H, br. s, NH); δC (125 MHz,      
DMSO-d6) 21.0, 114.2, 120.0, 121.1, 125.6, 126.4, 127.2, 128.2, 
128.4, 131.9, 132.8, 134.4, 136.4, 138.0, 141.4, 142.7, 150.9, 
176.7, 181.0; m/z (ESI-) 476 ([M-H]-, 100%); HRMS (ESI+) 
C24H19N3NaO6S ([M+Na]+) requires 500.0887, found 500.0863; 
λmax (pH 8) 529 nm (εN 7720 M-1cm-1), λmax (pH 13.75) 616 nm 
(εCB 3880 M-1cm-1); pKa 8.0. 
 
4.1.59. N-(3-(3’’,5’’-Dimethylphenylamino)-8-nitro-1,4-dioxo-
1,4-dihydronaphthalen-2-yl)benzenesulfonamide (77) 
Following Representative Procedure 2, using 
naphthoquinone 73 (60 mg, 0.15 mmol), 3,5-dimethylaniline (57 
µL, 0.46 mmol) and CeCl3.7H2O (58 mg, 0.15 mmol) in toluene 
(10 mL) at 110 °C. Purification via column chromatography on 
silica gel (eluent pet ether:acetone 75:25) and subsequent 
recrystallisation from toluene gave 3-anilinonaphthoquinone 77 
as a purple solid (8 mg, 11%). mp 218-220 °C (toluene); HPLC 
(method B) tR 9 min., 99%; υmax (KBr) 3298 (N-H), 3219 (N-H), 
1678 (C=O), 1641 (C=O); δH (400 MHz, DMSO-d6) 2.22 (6H, s, 
2 x Ar-Me), 6.60 (2H, s, H2’’ and H6’’), 6.68 (1H, s, H4’’), 7.32-
7.40 (2H, m, H3’ and H5’), 7.46-7.55 (3H, m, H2’, H4’ and H6’), 
7.94 (1H, app. t, J 7.9, H6), 8.05 (1H, dd, J 7.9, 1.0, H5 or H7), 
8.22 (1H, dd, J 7.9, 1.0, H5 or H7), 9.07 (1H, s, NH), 9.08 (1H, s, 
NH); δC (100 MHz, DMSO-d6) 21.8, 114.1, 122.2, 123.0, 126.6, 
127.2, 129.0, 129.3, 129.4, 132.4, 132.8, 135.0, 137.2, 138.6, 
141.8, 143.4, 148.6, 176.2, 181.6; m/z (ESI-) 476 ([M-H]-, 
100%); HRMS (ESI+) C24H19N3NaO6S+ ([M+Na]+) requires 
500.0887, found 500.0882; λmax (pH 8) 515 nm (εN 
5500 M-1cm-1), λmax (pH 13.75) 573 nm (εCB 2740 M-1cm-1); pKa 
8.6. 
 
4.1.60. N-(8-Nitro-1,4-dioxo-3-(phenylamino)-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (78) 
Following Representative Procedure 2, using 
naphthoquinone 73 (100 mg, 0.26 mmol), aniline (70 µL, 0.77 
mmol) and CeCl3.7H2O (95 mg, 0.26 mmol) in toluene (10 mL) 
at 110 °C. Purification via column chromatography on silica gel 
(eluent pet ether:acetone 75:25) and subsequent recrystallisation 
from toluene gave 3-anilinonaphthoquinone 78 as a purple solid 
(30 mg, 26%). mp 231-233 °C (toluene); HPLC (method A) 
tR 24 min., 98%; υmax (KBr) 3330 (N-H), 1673 (C=O), 1649 
(C=O); δH (500 MHz, DMSO-d6) 7.03-7.12 (3H, m, H2’’, H4’’ and 
H6’’), 7.22-7.29 (2H, m, H3’’ and H5’’), 7.34-7.41 (2H, m, H3’ and 
H5’), 7.48-7.57 (3H, m, H2, H4’ and H6’), 7.91-7.96 (1H, m, H6), 
8.03 (1H, dd, J 7.8, 1.0, H7), 8.23 (1H, dd, J 7.8, 1.0, H5), 9.04 
(1H, s, sulfonamide-NH), 9.28 (1H, s, aniline-NH); δC (125 MHz, 
DMSO-d6) 113.1, 122.0, 123.9, 124.1, 126.5, 127.4, 128.1, 
128.5, 128.5, 131.6, 132.2, 134.2, 138.1, 140.8, 142.6, 147.7, 
175.0, 180.7; m/z (ESI-) 448 ([M-H]-, 100%); HRMS (ESI-) 
C22H14N3O6S- ([M-H]-) requires 448.0609, found 448.0591; λmax 
(pH 8) 504 nm (εN 3510 M-1cm-1), λmax (pH 13.75) 578 nm (εCB 
3010 M-1cm-1); pKa 8.4. 
 
4.1.61. N-(5-Amino-3-(3’’,5’’-dimethylphenylamino)-1,4-
dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide (79) 
Following Representative Procedure 7, using 
naphthoquinone 74 (22 mg, 0.05 mmol) and 10% Pd/C (1.0 mg, 
0.01 mmol) in MeOH (2 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 90:10 to 
75:25) gave 5-aminonaphthoquinone 79 as an orange solid 
(20mg, quant.). mp 232-234 °C; HPLC (method B) tR 9 min., 
  
95%; υmax (KBr) 3464 (N-H), 3300 (N-H), 1573 (br., C=O); 
δH (400 Hz, DMSO-d6) 2.21 (6H, s, 2 x Ar-Me), 6.58 (2H, s, H2’’ 
and H6’’), 6.64 (1H, s, H4’’), 7.01-7.08 (2H, m, H6 and H8), 7.32-
7.43 (3H, m, H7, H3’ and H5’), 7.46-7.52 (3H, m, H2’, H4’ and H6’), 
7.88 (2H, br. s, NH2), 8.60 (1H, s, aniline-NH), 8.86 (1H, s, 
sulfonamide-NH); δC (100 MHz, DMSO-d6) 21.9, 109.0, 113.3, 
115.9, 121.7, 123.0, 126.0, 127.2, 129.2, 132.6, 133.3. 136.0, 
137.2, 138.8, 142.2, 143.1, 152.5, 179.6, 182.9; m/z (ESI+) 470 
([M+Na]+, 100%); HRMS (ESI+) C24H21N3NaO4S+, ([M+H]+) 
requires 448.1326; found 448.1326; λmax (pH 8) 474 nm 
(εN 22420 M-1cm-1), λmax (pH 13.75) 490 nm (εCB 15800 M-1cm-1). 
 
4.1.62. N-(6-Amino-3-(3’’,5’’-dimethylphenylamino)-1,4-
dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide (80) 
Following Representative Procedure 7, using 
naphthoquinone 75 (26 mg, 0.06 mmol) and 10% Pd/C (1.2 mg, 
0.01 mmol) in MeOH (2 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 80:20) 
gave 6-aminonaphthoquinone 80 as a brown solid (24 mg, 
quant.). mp 282-288 °C; HPLC (method A) tR 24 min., >99%; 
υmax (neat) 3475 (N-H), 3372 (N-H), 1589 (br., C=O); 
δH (500 MHz, DMSO-d6) 2.21 (6H, s, 2 x Ar-Me), 6.36 (2H, s, 
NH2), 6.51 (2H, s, H2’’ and H6’’), 6.59 (1H, s, H4’’), 6.81 (1H, dd, 
J 8.5, 2.5, H7), 7.12 (1H, d, J 2.5, H5), 7.34-7.39 (2H, m, H3’ and 
H5’), 7.47-7.55 (4H, m, H8, H2’, H4’ and H6’), 8.32 (1H, s, aniline-
NH), 8.94 (1H, br. s, sulfonamide-NH); δC (125 MHz, DMSO-d6) 
21.0, 109.7, 115.5, 117.8, 119.3, 119.8, 124.3, 126.3, 128.1, 
128.3, 131.9, 132.0, 136.4, 138.7, 140.0, 141.2, 153.4, 178.2, 
183.2; m/z (ESI+) 470 ([M+Na]+, 100%); HRMS (ESI+) 
C24H21N3NaO4S+ ([M+Na]+) requires 470.1145, found 470.1142; 
λmax (pH 8) 398 nm (εN 9830 M-1cm-1), λmax (pH 13.75) 389 nm 
(εCB 12540 M-1cm-1). 
 
4.1.63. N-(7-Amino-3-(3’’,5’’-dimethylphenylamino)-1,4-
dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide (81) 
Following Representative Procedure 7, using 
naphthoquinone 76 (40 mg, 0.08 mmol) and 10% Pd/C (1.8 mg, 
0.02 mmol) in MeOH (2 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 85:15) 
gave 7-aminonaphthoquinone 81 as an orange solid (29 mg, 
77%). mp 255-258 °C; HPLC (method A) tR 24 min., 97%; 
υmax (neat) 3364 (N-H), 1579 (br., C=O); δH (500 MHz, 
DMSO-d6) 2.22 (6H, s, 2 x Ar-Me), 6.58 (2H, s, H2’’ and H6’’), 
6.64 (1H, s, H4’’), 6.71 (2H, s, NH2), 6.74 (1H, dd, J 8.5, 2.2, H6), 
6.96 (1H, d, J 2.2, H8), 7.33-7.39 (2H, m, H3’ and H5’), 7.46-7.53 
(3H, m, H2, H4’ and H6’), 7.73 (1H, d, J 8.5, H5), 8.60 (1H, s, 
aniline-NH), 8.80 (1H, s, sulfonamide-NH); δC (125 MHz, 
DMSO-d6) 21.0, 109.8, 111.8, 115.7, 117.6, 121.0, 125.2, 126.3, 
128.3, 129.4, 131.8, 134.2, 136.3, 137.9, 141.4, 142.2, 155.4, 
179.1, 179.3; m/z (ESI-) 446 ([M-H]-, 100%); HRMS (ESI+) 
C24H21N3NaO4S+ ([M+Na]+) requires 470.1145, found 470.1139; 
λmax (pH 8) 410 nm (εN 37310 M-1cm-1), λmax (pH 13.75) 420 nm 
(εCB 21890 M-1cm-1). 
 
4.1.64. N-(8-Amino-3-(3’’,5’’-dimethylphenylamino)-1,4-
dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide (82) 
Following Representative Procedure 7, using 
naphthoquinone 77 (60 mg, 0.13 mmol) and 10% Pd/C (2.7 mg, 
0.03 mmol) in MeOH (2 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 75:25 to 
60:40) gave 8-aminonaphthoquinone 82 as a magenta solid 
(56 mg, quant.). mp 223-225 °C; HPLC (method B) tR 9 min., 
95%; υmax (KBr) 3337 (N-H), 3295 (N-H), 1661 (C=O), 1618 
(C=O); δH (400 MHz, DMSO-d6) 2.20 (6H, s, 2 x Ar-Me), 6.50 
(2H, s, H2’’ and H6’’), 6.59 (1H, s, H4’’), 7.09 (1H, d, J 8.4, H7), 
7.25 (1H, d, J 7.0, H5), 7.33-7.42 (5H, m, H6, H3’, H5’ and NH2), 
7.47-7.55 (3H, m, H2’, H4’ and H6’), 8.35 (1H, s, aniline-NH), 
8.96 (1H, s, sulfonamide-NH); δC (100 MHz, DMSO-d6) 21.9, 
110.1, 116.4, 116.5, 120.9, 125.2, 125.4, 127.2, 129.2, 132.2, 
132.8, 134.1, 137.2, 139.4, 140.8, 141.9, 151.3, 182.7, 183.4; 
m/z (ESI-) 470 ([M+Na]+, 100%); HRMS (ESI+) C24H21N3NaO4S+ 
([M+Na]+) requires 470.1145, found 470.1147; λmax (pH 8) 542 
nm (εN 15090 M-1cm-1), λmax (pH 13.75) 479 nm (εCB                       
12380 M-1cm-1); pKa 8.4. 
 
4.1.65. N-(8-Amino-1,4-dioxo-3-(phenylamino)-1,4-
dihydronaphthalen-2-yl)benzenesulfonamide (83) 
Following Representative Procedure 7, using 
naphthoquinone 78 (25 mg, 0.06 mmol) and 10% Pd/C (1.2 mg, 
0.01 mmol) in MeOH (2 mL). Purification via column 
chromatography on silica gel (eluent pet ether:acetone 80:20) 
gave 8-aminonaphthoquinone 83 as a magenta solid (22 mg, 
quant.). mp 242-244 °C; HPLC (method A) tR 25 min., >99%; 
υmax (neat) 3459 (N-H), 3335 (N-H), 1618 (br., C=O); 
δH (500 MHz, DMSO-d6) 6.93-6.97 (2H, m, H2’’ and H6’’), 6.98-
7.02 (1H, m, H4’’), 7.08 (1H, dd, J 8.5, 1.1, H7), 7.18-7.23 (2H, 
m, H3’’ and H5’’), 7.26 (1H, dd, J 7.3, 1.1, H5), 7.36-7.40 (3H, m, 
H6, H3’ and H5’), 7.48-7.52 (1H, m, H4’), 7.54-7.58 (2H, m, H2’ 
and H6’), 8.57 (1H, s, NH), 8.90 (1H, s, NH); δC (125 MHz, 
DMSO-d6) 109.2, 115.1, 115.6, 122.5, 122.7, 124.2, 126.5, 
127.5, 128.5, 131.4, 132.1, 133.2, 138.9, 140.0, 140.9, 150.3, 
181.6, 182.5; m/z (ESI+) 442 ([M+Na]+, 100%); HRMS (ESI+) 
C22H17N3NaO4S+ ([M+Na]+) requires 442.0832, found 442.0821; 
λmax (pH 8) 514 nm (εN 16660 M-1cm-1), λmax (pH 13.75) 486 nm 
(εCB 15840 M-1cm-1); pKa 8.2. 
 
4.2 Biology 
 
4.2.1. General Experimental 
Molecular biology reagents and competent E. coli cells were 
purchased from Promega (Southampton, UK). 
 
4.2.2. Expression and Purification of mNat2, hNAT1 and 
shNat2 
Recombinant mNat2 with an N-terminal hexa-His tag was 
expressed from E. coli Rosetta®(-DE3)pLysS cells containing 
pET28b(+), into which the mNat2 open-reading frame had been 
sub-cloned.39 The protein was purified via Ni-NTA affinity 
chromatography (Qiagen) and thrombin cleavage of the His tag, 
as previously described.22 Both pure recombinant hNAT128, 40 and 
shNat232 were produced as previously described. 
The concentrations of solutions containing purified proteins 
were determined by measuring their absorption at 280 nm and 
using the molar extinction coefficients calculated for each 
enzyme. The purified NATs were stored at -80 °C in 20 mM 
Tris.HCl (pH 8.0) buffer solution containing 5 mM dithiothreitol 
and 5% (v/v) glycerol at the following concentrations: mNat2 
8 mg/mL; hNAT1 1.5 mg/mL; shNat2 20 mg/mL. These 
solutions were diluted as required on the day of use. 
 
4.2.3. ZR-75-1 Breast Cancer Cell Line Studies 
4.2.3.1. Growth of ZR-75-1 Cells. Cells from the human breast 
cancer cell line ZR-75-1, which had previously been stored in 
liquid N2, were grown in RMPI 1640 L-glutamine-containing 
growth medium, with 10% (v/v) foetal calf serum and 1% (v/v) 
Pen/Strep/Glutamine added, at 37 °C in a 5% CO2 environment. 
Cell growth was monitored at regular intervals and once almost 
confluent (every 5-7 days) the cells were split in a 1:2 fashion, 
using Trypsin-EDTA solution (0.25% (w/v)) to detach the cell 
monolayer from the culture flask. After 5 passages, the cells were 
harvested to prepare a lysate, by resuspending the cell pellet in 
complete lysis buffer (100 µL frozen protease inhibitors and 
  
10 µL 100 mM dithiothreitol added per 900 µL of lysis buffer 
(20 mM Tris, 20 mM NaCl, 0.5% (w/v) Nonidet P40 containing 
one EDTA-free Complete Protease Inhibitor per 2.5 mL)) to a 
final cell concentration of 5 x 107 cells/mL. Cell debris was 
removed by centrifugation (10 min., 4 °C, 14000 rpm, 
microfuge) and the supernatant retained. The cell lysate was kept 
on ice and all studies with inhibitors were carried out on the same 
day. 
4.2.3.2. Quantification of hNAT1 in ZR-75-1 Cell Extracts by 
Western and Dot Blotting. For Western Blotting, ZR-75-1 cell 
extract samples were run on a 12% SDS-PAGE gel, using 8 µL 
sample and 2 µL reduced gel loading buffer (10 mM Tris.HCl 
(pH 6.8), 8 M urea, 2% (w/v) SDS, 5 mg/mL DTT) per well. 
Following transfer to PVDF micro-porous membranes in a 
suitable buffer (48 mM Tris.HCl (pH 8.3), 39 mM glycine, 20% 
MeOH) for 4 h using a semi-dry blotter, membranes were 
blocked with 10% milk in Tris-Buffered Saline Tween-20 (9 g/L 
NaCl, 6 g/L Tris.HCl, 0.05% (v/v) Tween-20), washed thrice 
with 3% milk and incubated with the polyclonal antibody 19525 at 
a dilution of 1:2000 for 1 h. Membranes were subsequently 
incubated with horseradish peroxidise-conjugated mouse anti-
rabbit IgG at a dilution of 1:10000 for 1 h as a secondary 
antibody. Bound mNat2 and hNAT1 were detected using a 
chemiluminescent kit (ECL Reagent Kit, Amersham). For Dot 
Blotting, the samples (200 µL/well containing 100 µL of 
recombinant mNat2 or ZR-75-1 cell lysate) were directly 
transferred onto a PVDF membrane using the Bio-Dot® 
Microfiltration Apparatus and a procedure similar to Western 
Blotting was used to detect the relevant protein. 
 
4.2.4. Acetyl CoA Hydrolysis Assay 
The rate of production of free thiol Coenzyme A (CoA-SH) 
by NATs in the presence of both an arylamine and AcCoA was 
measured in end-point assays using Ellman’s reagent, 5,5’-dithio-
bis-(2-nitrobenzoic acid) (DTNB), as previously described.29 The 
final NAT concentration in each assay well was 1.5 µg/mL. 
For a preliminary test of inhibitory potency of a compound at 
30 µM, assays were conducted in triplicate and the specific NAT 
activity was calculated from a graph of the OD405, measured on a 
plate reader (Tecan Sunrise), against time. The % retained 
specific activity was calculated against a control assay without 
inhibitor. In IC50 tests, a range of ten concentrations was selected 
for each compound, most often beginning at 10, 30 or 50 µM and 
diluting by a factor of two in each subsequent well. Assays were 
conducted in duplicate and % specific activity for each assay was 
determined relative to a control without inhibitor. KyPlot® 
software was used to determine the IC50 value from a plot of % 
retained specific activity against inhibitor concentration using the 
IC50%FUN regression model. 
 
4.2.5. Colorimetric Evaluation of Inhibitors 
4.2.5.1. Spectrophotometry. Visible spectra of each compound 
were recorded using a U-2001 spectrophotometer (Hitachi) and 
50 µL UVettes® (Eppendorf). The compounds were tested at 15 
µM in buffer solutions containing 5% (v/v) DMSO at pH 8 (20 
mM Tris.HCl), pH 13.75 (4 M NaOH) and, where relevant, in the 
presence of mNat2 and/or hNAT1 (30 µM in 20 mM Tris.HCl). 
All spectra were blank-corrected and normalised. 
4.2.5.2. Determination of pKa Values. Full absorbance spectra 
of selected compounds at 100 µM in 14 appropriately buffered 
solutions containing 5% (v/v) DMSO in a flat-bottomed 96-well 
plate (Corning) were recorded on a plate reader (Omega). 
Recorded spectra were blank-corrected and normalised before 
λmax was determined. A graph of λmax against pH was then plotted 
for each inhibitor using GraphPad® software. A sigmoidal dose-
response (variable slope) regression model was used to determine 
the pKa by the method of least squares. 
4.2.5.3. Determination of Absorption Coefficients. Full 
absorbance spectra of selected compounds at 200 µM, 100 µM, 
50 µM and 25 µM in buffer solutions at pH 8 or 13 containing 
5% (v/v) DMSO in a 96-well flat-bottomed plate (Corning) were 
recorded on a plate reader (Omega). Spectra were blank-
corrected and normalised and experiments performed in 
duplicate. A plot of absorbance at λmax against concentration then 
yielded the absorption coefficient, at either pH 8 (εN) or pH 13 
(εCB), as the gradient divided by the path length. 
4.2.6. Docking Studies 
All images showing protein structures were generated using 
the software PyMOL (W. L. DeLano (2002) PyMOL, DeLano 
Scientific, San Carlos, CA). Prior to docking a ligand into the 
hNAT1 active site (pdb: 2PQT)12e, the ground state conformation 
of the ligand was predicted using the molecular editor 
Avogadro,41 and the protein was protonated to be consistent with 
the assay conditions of pH 8. The docking simulations and the 
analysis of the possible interactions between the protein and the 
ligand were performed using GOLD®.30 The docking site was 
defined as a region of 10 Å within the active pocket of the 
enzyme and the generated solutions were ranked using the 
GOLD® Score Fitness function.30 Each docking simulation was 
repeated ten times to ensure the observed solutions were 
consistent. 
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